TOMI Environmental Q3 net loss narrows to $189K
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
TOMI Environmental Solutions, Inc. (TOMZ) reported third-quarter 2026 sales of $2.49 million, up approximately 24% from $2.01 million a year earlier. Operating income was $30,047, compared with an operating loss of $321,415, and net loss narrowed to $188,986 from $450,348. Gross margin was 59.0%, down from 61.2%. Nine-month sales were $6.39 million versus $4.62 million.
Cash used in operations was $1.56 million for nine months, compared with $576,780 a year earlier; cash and equivalents were $195,162 as of September 30, 2026. TOMZ issued 1,558,642 shares through its equity line, generating $2,199,586 in net proceeds, and converted $2.5 million of amended notes into 1,666,655 shares, leaving $635,000 of note principal outstanding as of September 30, 2026. Sales-order backlog was $2.5 million as of September 30, 2026, and later increased to $2.8 million; its $35 million pipeline represents potential, not committed, sales. TOMZ and Carbonium Core mutually terminated their merger agreement on September 15, 2026. Niroshan Srirathan was appointed permanent CFO effective October 11, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter revenue rose 24% year over year to $2.49 million.
- Moderate pointThird-quarter net loss narrowed to $188,986 from $450,348 year over year.
Negative
- Moderate pointNine-month operating cash use increased to $1.56 million from $576,780.
Filing Explained
TOMI says it is evaluating how to meet the resale-registration obligation; penalties for missing contractual deadlines are not estimated.
As of
TOMI had not filed the agreed resale registration statement for shares issuable under the 2025 notes and says it is evaluating when and how to meet that obligation; missing the contractual deadlines could trigger liquidated damages or other penalties that the company cannot estimate.
Key Figures
Key Terms
ELOC financial
non-GAAP net loss financial
anti-dilutive financial
valuation allowance financial
Binary Ionization Technology technical
ionized Hydrogen Peroxide technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did TOMZ report for Q3 2026?
How much did TOMZ receive from its equity line in the first nine months of 2026?
How much convertible debt did TOMZ convert in Q3 2026?
What happened to TOMZ's Carbonium Core merger?
Can Abbott Nutrition facilities use TOMZ's iHP technology?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
or
For the transition period from _____ to _____
Commission File Number:

(Exact name of registrant as specified in its charter) |
| ||
(State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code) | |
|
|
( | |
(Registrant’s telephone number, including area code) | |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
☒ | Smaller reporting company | ||
|
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of November 16, 2026, the registrant had
QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2026 | ||
|
|
|
TABLE OF CONTENTS | ||
|
|
|
|
| Page |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS | 3 | |
|
|
|
PART I | FINANCIAL INFORMATION |
|
|
|
|
Item 1 | Financial Statements. | 4 |
|
|
|
Item 2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations. | 28 |
|
|
|
Item 3 | Quantitative and Qualitative Disclosures About Market Risk. | 40 |
|
|
|
Item 4 | Controls and Procedures. | 40 |
|
|
|
PART II | OTHER INFORMATION |
|
|
|
|
Item 1 | Legal Proceedings. | 42 |
|
|
|
Item 1A | Risk Factors. | 42 |
|
|
|
Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds. | 43 |
|
|
|
Item 3 | Defaults Upon Senior Securities. | 43 |
|
|
|
Item 4 | Mine Safety Disclosures. | 43 |
|
|
|
Item 5 | Other Information. | 43 |
|
|
|
Item 6 | Exhibits. | 43 |
|
|
|
SIGNATURES | 44 | |
|
| |
EXHIBIT INDEX | 45 | |
| 2 |
| Table of Contents |
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, or this Form 10-Q, contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Form 10-Q, except for historical information, may be deemed forward-looking statements. You can generally identify forward-looking statements as statements containing the words "will," "would," "believe," "expect," "estimate," "anticipate," "intend," "assume," "can," "could," "plan," "predict," "should" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements.
Forward-looking statements involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section "Risk Factors" in our recent annual report on Form 10-K previously filed with the Securities and Exchange Commission on March 31, 2026.
Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
| 3 |
| Table of Contents |
PART I: FINANCIAL INFORMATION
Item 1. Financial Statements.
TOMI ENVIRONMENTAL SOLUTIONS, INC. | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
|
|
|
|
| ||||
|
| As of September 30, |
|
| As of December 31, |
| ||
|
| 2026 |
|
| 2025 |
| ||
|
| (Unaudited) |
|
|
| |||
|
|
|
|
|
|
| ||
ASSETS |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ |
|
| $ |
| ||
Accounts receivable, net |
|
|
|
|
|
| ||
Inventories, net (Note 3) |
|
|
|
|
|
| ||
Vendor deposits (Note 4) |
|
|
|
|
|
| ||
Prepaid expenses |
|
|
|
|
|
| ||
Other current assets |
|
|
|
|
|
| ||
Total current assets |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Property and equipment, net (Note 5) |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Other assets: |
|
|
|
|
|
|
|
|
Intangible assets, net (Note 6) |
|
|
|
|
|
| ||
Operating lease – right of use asset (Note 7) |
|
|
|
|
|
| ||
Other assets |
|
|
|
|
|
| ||
Total other assets |
|
|
|
|
|
| ||
Total assets |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
| $ |
|
| $ |
| ||
Accrued expenses and other current liabilities (Note 12) |
|
|
|
|
|
| ||
Deferred revenue |
|
|
|
|
|
| ||
Sale of future receipts, net of discount of $ |
|
|
|
|
|
| ||
Current portion of long-term operating lease (Note 7) |
|
|
|
|
|
| ||
Total current liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Long-term liabilities: |
|
|
|
|
|
|
|
|
Long-term operating lease, net of current portion (Note 7) |
|
|
|
|
|
| ||
Convertible notes payable, net of unamortized discount of $ |
|
|
|
|
|
| ||
Total long-term liabilities |
|
|
|
|
|
| ||
Total liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Notes 7, 8, 10 and 11) |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Cumulative convertible Series A preferred stock; par value $ |
| $ |
|
| $ |
| ||
Cumulative convertible Series B preferred stock; $ |
|
|
|
|
|
| ||
Common stock; par value $ |
|
|
|
|
|
| ||
Additional paid-in capital |
|
|
|
|
|
| ||
Accumulated deficit |
|
| ( | ) |
|
| ( | ) |
Total shareholders’ equity |
|
|
|
|
|
| ||
Total liabilities and shareholders' equity |
| $ |
|
| $ |
| ||
The accompanying notes are an integral part of the condensed consolidated financial statements.
| 4 |
| Table of Contents |
TOMI ENVIRONMENTAL SOLUTIONS, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(UNAUDITED) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
| For the three months ended |
|
| For the nine months ended |
| ||||||||||
|
| September 30, |
|
| September 30, |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Sales, net |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Cost of sales |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Selling expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Research and development |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Consulting fees |
|
|
|
|
|
|
|
|
|
|
|
| ||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Income (Loss) from operations |
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (Employee Retention Credit) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest expense |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Loss on extinguishment of convertible debt |
|
| ( |
|
|
| |
|
|
| ( |
|
|
| |
|
Total other income (expense) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income taxes |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Provision for income taxes (Note 13) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net loss |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
Diluted |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic weighted average common shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Diluted weighted average common shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
| ||||
The accompanying notes are an integral part of the condensed consolidated financial statements.
| 5 |
| Table of Contents |
TOMI ENVIRONMENTAL SOLUTIONS, INC. | ||||||||||||||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY | ||||||||||||||||||||||||||||
For the three and nine months ended September 30, 2026 and 2025 | ||||||||||||||||||||||||||||
(UNAUDITED) | ||||||||||||||||||||||||||||
As Adjusted for 1-for-3 Reverse Stock Split
| ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
| Total |
| ||||||||||||||||||
|
| Series A Preferred |
|
| Common Stock |
|
| Additional |
|
| Accumulated |
|
| shareholders' |
| |||||||||||||
Three Months Ended September 30, 2026 |
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| paid-in capital |
|
| deficit |
|
| equity |
| |||||||
Balance at July 1, 2026 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||
Conversion of amended convertible notes to common stock at fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
Common stock issued pursuant to ELOC, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
Net (loss) for the three months ended September 30, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
Balance at September 30, 2026 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred |
|
| Common Stock |
|
| Additional |
|
| Accumulated |
|
| Total shareholders' |
| |||||||||||||
Nine Months Ended September 30, 2026 |
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| paid-in capital |
|
| deficit |
|
| equity |
| |||||||
Balance at January 1, 2026 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||
Director compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ |
| ||||
Equity compensation expense related to RSU's |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ |
| ||||
Common stock issued pursuant to ELOC, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ |
| ||||
Conversion of amended convertible notes to common stock at fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ |
| |||||
Net (loss) for the nine months ended September 30, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
| $ | ( | ) |
Balance at September 30, 2026 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred |
|
| Common Stock |
|
| Additional |
|
| Accumulated |
|
| Total shareholders' |
| |||||||||||||
Three Months Ended September 30, 2025 |
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| paid-in capital |
|
| deficit |
|
| equity |
| |||||||
Balance at July 1, 2025 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||
Net (loss) for the three months ended September 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) | ||
Balance at September 30, 2025 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred |
|
| Common Stock |
|
| Additional |
| Accumulated |
| Total shareholders' |
| |||||||||||||||
Nine Months Ended September 30, 2025 |
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| paid-in capital |
|
| deficit |
|
| equity |
| |||||||
Balance at January 1, 2025 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||
Director compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
Net (loss) for the nine months ended September 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
Balance at September 30, 2025 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||
The accompanying notes are an integral part of the condensed consolidated financial statements.
| 6 |
| Table of Contents |
TOMI ENVIRONMENTAL SOLUTIONS, INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(UNAUDITED) | ||||||||
|
|
|
|
|
|
| ||
|
| For the nine months ended September 30, |
| |||||
|
| 2026 |
|
| 2025 |
| ||
|
|
|
|
|
|
| ||
Cash flows from operating activities: |
|
|
|
|
|
| ||
Net loss |
| $ | ( | ) |
| $ | ( | ) |
Adjustments to reconcile net loss to net cash (used in) operating activities: |
|
|
|
|
|
|
|
|
Loss on extinguishment of convertible debt |
|
| |
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
| ||
Amortization of right of use asset |
|
|
|
|
|
| ||
Amortization of discount on convertible debt |
|
|
|
|
|
| ||
Amortization of sale of future receipts |
|
|
|
|
|
| ||
Equity compensation expense related to RSU's |
|
|
|
|
|
| ||
Director compensation |
|
|
|
|
|
| ||
Credit loss expense (benefit), net of financing discounts |
|
| ( | ) |
|
|
| |
Inventory reserve |
|
|
|
|
| ( | ) | |
Sales returns allowance |
|
|
|
|
| ( | ) | |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Decrease (increase) in: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
| ( | ) |
|
|
| |
Inventory |
|
|
|
|
|
| ||
Vendor deposits |
|
| ( | ) |
|
| ( | ) |
Prepaid expenses |
|
| ( | ) |
|
|
| |
Other current assets |
|
| ( | ) |
|
|
| |
Other assets |
|
| ( | ) |
|
|
| |
Increase (decrease) in: |
|
|
|
|
|
|
|
|
Accounts payable |
|
|
|
|
| ( | ) | |
Accrued expenses |
|
|
|
|
|
| ||
Deferred revenue |
|
| ( | ) |
|
|
| |
Lease liability |
|
| ( | ) |
|
| ( | ) |
Net cash (used in) operating activities |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Capitalized patent and trademark costs |
|
| ( | ) |
|
| ( | ) |
Purchase of property and equipment |
|
| ( | ) |
|
| ( | ) |
Net cash (used in) investing activities |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from ELOC, net of issuance costs |
|
|
|
|
|
| ||
Repayments of sale of future receipts |
|
| ( | ) |
|
|
| |
Proceeds from issuance of convertible notes |
|
|
|
|
|
| ||
Net cash provided by financing activities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents |
|
|
|
|
| ( | ) | |
Cash and cash equivalents, beginning |
|
|
|
|
|
| ||
Cash and cash equivalents, ending |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
Supplemental cash flow information: |
|
|
|
|
|
|
|
|
Cash paid for interest |
| $ |
|
| $ |
| ||
Cash paid for income taxes |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Non-cash investing and financing activities: |
|
|
|
|
|
|
|
|
Equipment reclassified from inventory to fixed assets |
| $ |
|
| $ |
| ||
Equipment and inventory received in settlement of customer receivables |
| $ |
|
|
|
| ||
Conversion of amended convertible notes payable to common stock at fair value |
| $ |
|
|
|
| ||
ELOC proceeds receivable |
| $ |
|
|
|
| ||
The accompanying notes are an integral part of the condensed consolidated financial statements.
| 7 |
| Table of Contents |
TOMI ENVIRONMENTAL SOLUTIONS, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. DESCRIPTION OF BUSINESS
Overview
TOMI Environmental Solutions, Inc. ("TOMI," "we," "our," or the "Company") is a global provider of disinfection and decontamination solutions, offering environmentally friendly products and services for indoor air and surface treatment. Our flagship product line, SteraMist uses our patented Binary Ionization Technology (“BIT”) to deliver a low-concentration (7.8%) hydrogen peroxide-based fog or mist that effectively treats all indoor environments and surface areas.
Developed under a grant from the United States Defense Advanced Research Projects Agency (“DARPA”), SteraMist generates ionized Hydrogen Peroxide (“iHP”) through a high-voltage atmospheric cold plasma arc, converting hydrogen peroxide solution into submicron hydroxyl radical particles. This process achieves a 6-log (99.9999%) or greater kill rate against a broad spectrum of pathogens, leaving only oxygen and humidity as by-products. We maintain U.S. Environmental Protection Agency (“EPA”) registration for our BIT solution, along with applicable regulatory approvals in all 50 states, Washington D.C., Canada, and approximately 40 other countries.
We serve four primary market divisions: Life Sciences, Hospital-Healthcare, Food Safety, and Commercial. Within such industries, our revenue is derived from equipment sales, BIT Solution consumables, corporate decontamination services, and Installation/Operational/Performance Qualification (IQ/OQ/PQ) services.
Our mission: Innovating for a Safer World®.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The interim unaudited condensed consolidated financial statements included herein, presented in accordance with generally accepted accounting principles in the United States of America (GAAP), and stated in U.S. dollars, have been prepared by us, without an audit, pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures are adequate to make the information presented not misleading.
These financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. These unaudited condensed consolidated financial statements should be read in conjunction with our audited financial statements for the year ended December 31, 2025, and notes thereto which are included in the annual report on Form 10-K previously filed with the SEC on March 31, 2026, (the “Annual Report”). We follow the same accounting policies in the preparation of interim reports. The results of operations for the interim periods covered by this Form 10-Q may not necessarily be indicative of results of operations for the full fiscal year or any other interim period.
Reverse Stock Split. On July 20, 2026, the Company effected a 1-for-3 reverse stock split of its Common Stock and Series A Preferred Stock (the “Reverse Stock Split”). In connection with the Reverse Stock Split, every three shares of issued and outstanding Common Stock and Series A Preferred Stock were automatically combined into one share of the respective class of stock, without any change in the par value per share. The Reverse Stock Split did not change the number of authorized shares of Common Stock or Series A Preferred Stock. No fractional shares were issued in connection with the Reverse Stock Split, and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share.
The Reverse Stock Split also resulted in proportionate adjustments to the number of shares underlying the Company’s outstanding stock options, warrants and restricted stock units, as applicable, and corresponding adjustments to the exercise prices of outstanding options and warrants. All share and per-share amounts, including options, warrants, conversion prices and loss per share, have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented, unless otherwise indicated. See Note 9, Shareholders’ Equity, for additional information.
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of TOMI and its wholly owned subsidiary, TOMI Environmental Solutions, Inc., a Nevada corporation. All intercompany accounts and transactions have been eliminated in consolidation.
| 8 |
| Table of Contents |
Reclassification of Accounts
Certain reclassifications have been made to prior-year comparative financial statements to conform to the current year presentation. These reclassifications had no material effect on previously reported results of operations or financial position.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the accompanying consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate our estimates, including those related to allowance for credit losses, inventory, intangible assets, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes, and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of our assets and liabilities.
Fair Value Measurements
The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of input, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:
Level 1: | Quoted prices in active markets for identical assets or liabilities. |
Level 2: | Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities. |
Level 3: | Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities. |
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximated fair value because of the short maturity of these instruments.
The Company’s 2023 Notes and 2025 Notes are carried at amortized cost. Their estimated fair values are determined using a Monte Carlo simulation model that incorporates the Company’s stock price, expected volatility, the risk-free rate, and a discount rate reflecting the Company’s credit risk. These inputs are unobservable, so the fair values are classified within Level 3 of the fair value hierarchy.
Cash and Cash Equivalents
Cash and cash equivalents include cash on hand, held at financial institutions and other liquid investments with original maturities of three months or less. At times, these deposits may be more than insured limits. At September 30, 2026, and December 31, 2025, there were no cash equivalents.
Accounts Receivable
Accounts receivable is stated at the amount management expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. Management assesses the collectability of outstanding customer invoices and maintains an allowance resulting from the expected non-collection of customer receivables. In estimating this reserve, management considers factors such as industry sector, historical collection experience, customer creditworthiness, specific customer risk, and current and expected general economic conditions. For those customers to whom we extend credit, in accordance with the Current Expected Credit Loss (CECL) model, we make a risk-based evaluation at the point of sale which is then reviewed on both an individual and collective (pool) basis during each reporting period based on ASC 326.
Significant financing component. Certain customer contracts provide extended payment terms that include a financing component. For these contracts, the Company adjusts the transaction price for the time value of money using an imputed discount rate that reflects the customer’s credit risk and the payment term. The resulting present value discount reduces revenue and accounts receivable at inception and is accreted to interest income over the payment term using the effective interest method. The unamortized discount was $
| 9 |
| Table of Contents |
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| (Unaudited) |
|
|
|
| ||
Gross accounts receivable |
| $ |
|
| $ |
| ||
Less: Allowance for credit losses (breakdown below) |
|
| ( | ) |
|
| ( | ) |
Less: Allowance for sales returns |
|
| ( | ) |
|
| ( | ) |
Less: Present value discount (financing component) |
|
| ( | ) |
|
|
| |
Accounts receivable, net |
| $ |
|
| $ |
| ||
Movements on credit loss accounts are shown below:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| (Unaudited) |
|
|
|
| ||
Beginning reserve |
| $ |
|
| $ |
| ||
Credit loss expense (benefit) |
|
| ( | ) |
|
|
| |
Write-offs against previously reserved receivables |
|
| ( | ) |
|
| ( | ) |
Recoveries and adjustments |
|
|
|
|
| ( | ) | |
Ending reserve |
| $ |
|
| $ |
| ||
Inventories
Inventories are valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventories consist primarily of finished goods and raw materials. We expense costs to maintain certification to cost of goods sold as incurred.
We review inventory on an ongoing basis, considering factors such as deterioration and obsolescence, and future customer demand. We record an allowance for estimated losses when the facts and circumstances indicate that inventories may not be usable or realized when comparing current inventory levels to anticipated demand for our product. Our reserve for obsolete inventory was $
Property and Equipment
We account for property and equipment at cost less accumulated depreciation. We compute depreciation using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation commences for equipment, furniture and fixtures and vehicles, once placed in service for its intended use. Leasehold improvements are amortized using the straight-line method over the remaining lease term at the time the asset was placed into service or the service lives of the improvements, whichever is shorter.
Leases
We recognize a right-of-use (“ROU”) asset and lease liability for all leases with terms of more than 12 months, in accordance with ASC 842. We utilize the short-term lease recognition exemption for all asset classes as part of our on-going accounting under ASC 842. This means, for those leases that qualify, we will not recognize ROU assets or lease liabilities. Recognition, measurement and presentation of expenses depend upon classification as a finance or operating lease.
As a lessee, we utilize the reasonably certain threshold criteria in determining which options we will exercise. Furthermore, our lease payments are based on index rates with minimum annual increases. These represent fixed payments and are captured in the future minimum lease payments calculation. In determining the discount rate to use in calculating the present value of lease payments, we used our incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments.
We have also elected the practical expedient not to separate lease and non-lease components for all asset classes, meaning all consideration that is fixed, or in-substance fixed, will be captured as part of our lease components for balance sheet purposes. Furthermore, all variable payments included in lease agreements will be disclosed as variable lease expense when incurred. Generally, variable lease payments are based on usage and common area maintenance. These payments will be included as variable lease expense in the period in which they are incurred.
| 10 |
| Table of Contents |
Vendor Concentration
The Company is dependent on a limited number of third-party suppliers for the manufacture of its SteraMist® line of equipment and for the supply of its BIT Solution. This dependence results in concentration of both purchasing activity and accounts payable balances among a small number of vendors.
As of September 30, 2026, accounts payable to Vendor A and Vendor B accounted for approximately
For the three and nine months ended September 30, 2026, two vendors collectively accounted for approximately
The Company remains committed to diversifying its supplier base, though it is substantially dependent on these vendors for its primary product lines. Any disruption to these relationships could have a material adverse effect on the Company's ability to fulfill customer orders and on its results of operations. Refer to Item 1A, Risk Factors, as disclosed in the Company’s Form 10-K, for further discussion of risks related to its reliance on third-party manufacturers and suppliers.
Income Taxes
The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A significant area of judgment relates to the realization of deferred tax assets, including net operating loss carryforwards and other deductible temporary differences. The Company evaluates the realizability of its deferred tax assets based on available evidence, including historical operating results, projections of future taxable income, and the expected reversal of temporary differences.
Based on the Company’s recent history of operating losses, management has concluded that it is more likely than not that its deferred tax assets will not be realized. Accordingly, the Company has recorded a full valuation allowance against its deferred tax assets. The valuation allowance will be maintained until sufficient positive evidence exists to support the realization of these assets.
Additional information regarding the Company’s income taxes, including deferred tax assets and net operating loss carryforwards, is included in Note 13. Income Taxes to the consolidated financial statements.
Net Loss Per Share
Basic net loss per share is computed by dividing our net loss by the weighted average number of shares of common stock outstanding during the period presented. Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of shares of common stock, such as shares issuable pursuant to the exercise of options and warrants and conversions of preferred stock or debentures. The computation of diluted EPS is similar to the computation of basic EPS except that the numerator may have to adjust for any dividends and income or loss associated with potentially dilutive securities that are assumed to have resulted in the issuance of shares of common stock and the denominator may have to adjust to include the number of additional shares of common stock that would have been outstanding if the dilutive potential shares of common stock had been issued during the period to reflect the potential dilution that could occur from shares of common stock issuable through a contingent shares issuance arrangement, stock options, warrants, or convertible preferred stock. For purposes of determining diluted earnings per common share, the treasury stock method is used for stock options, and warrants, and the if-converted method is used for convertible preferred stock as prescribed in FASB ASC Topic 260. Because of the net loss for the three and nine months ended September 30, 2026 and 2025, the impact of including these in our computation of diluted EPS was anti-dilutive.
| 11 |
| Table of Contents |
Potentially dilutive securities as of September 30, 2026 and 2025 consisted of the following, as adjusted for our recent stock split:
|
| September 30, 2026 |
|
| September 30, 2025 |
| ||
Convertible debentures |
|
|
|
|
|
| ||
Stock warrants |
|
|
|
|
|
| ||
Stock options |
|
|
|
|
|
| ||
Convertible Series A Preferred Stock |
|
|
|
|
|
| ||
Total |
|
|
|
|
|
| ||
Warrants, options, preferred stock and shares associated with the conversion of debt to purchase approximately
|
| For the three months ended September 30, |
|
| For the nine months ended September 30, |
| ||||||||||
|
| (Unaudited) |
|
| (Unaudited) |
|
| (Unaudited) |
|
| (Unaudited) |
| ||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net loss |
| ($ |
|
| ($ |
|
| ($ |
|
| ($ |
| ||||
Net loss attributable to common shareholders |
| ($ |
|
| ($ |
|
| ($ |
|
| ($ |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic weighted average common shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Diluted weighted average common shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
| ($ |
|
| ($ |
|
| ($ |
|
| ($ |
| ||||
Diluted |
| ($ |
|
| ($ |
|
| ($ |
|
| ($ |
| ||||
Revenue Recognition
We recognize revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition, we perform the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy the performance obligations.
We must use judgment to determine: (a) the number of performance obligations and whether they are distinct from one another; (b) the transaction price; and (c) the standalone selling price for each performance obligation for purposes of transaction price allocation.
Title and risk of loss generally pass to our customers upon shipment. Shipping and handling costs charged to customers are included in product revenues, and the associated expenses are treated as fulfillment costs included in cost of revenues. Revenues are reported net of sales taxes collected from customers.
Product revenue includes sales of our standard and customized equipment, BIT Solution and accessories, recognized upon transfer of control to the customer. Service and training revenue includes high-level decontamination engagements, equipment validation and customer training, recognized as the agreed-upon services are rendered.
A portion of our revenue is derived from SteraMist Integrated Systems ("SIS") and Custom Engineered Systems ("CES"), which may involve multiple performance obligations including equipment supply, installation, validation and ongoing service. For these arrangements, management exercises significant judgment in identifying and allocating the transaction price among the distinct performance obligations and in determining the point at which control transfers to the customer. Delays in project completion or customer acceptance can affect the timing of revenue recognition.
We also record estimated allowances for sales returns, based on historical averages of return activity applied to our quarterly moving sales. As of September 30, 2026 and December 31, 2025, we recorded allowances of $
| 12 |
| Table of Contents |
Disaggregation of Revenue
The following table presents our revenues disaggregated by revenue source (rounded to nearest thousand).
Product and Service Revenue
|
| For the three months ended September 30, |
| |||||||||
|
| (Unaudited) |
| |||||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
Product |
| $ |
|
| $ |
|
| $ |
| |||
Service |
|
|
|
|
|
|
|
|
| |||
Total |
| $ |
|
| $ |
|
| $ |
| |||
Revenue by Geographic Region
|
| For the three months ended September 30, |
| |||||||||
|
| (Unaudited) |
| |||||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
United States |
| $ |
|
| $ |
|
| $ |
| |||
International |
|
|
|
|
|
|
|
| ( | ) | ||
Total |
| $ |
|
| $ |
|
| $ |
| |||
Product and Service Revenue
|
| For the nine months ended September 30, |
| |||||||||
|
| (Unaudited) |
| |||||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
Product |
| $ |
|
| $ |
|
| $ |
| |||
Service |
|
|
|
|
|
|
|
| ( | ) | ||
Total |
| $ |
|
| $ |
|
| $ |
| |||
Revenue by Geographic Region
|
| For the nine months ended September 30, |
| |||||||||
|
| (Unaudited) |
| |||||||||
|
| 2026 |
|
| 2025 |
|
| Change |
| |||
United States |
| $ |
|
| $ |
|
| $ |
| |||
International |
|
|
|
|
|
|
|
| ( | ) | ||
Total |
| $ |
|
| $ |
|
| $ |
| |||
| 13 |
| Table of Contents |
Costs to Obtain a Contract with a Customer
We apply a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. We generally expense sales commissions when incurred because the amortization period would have been one year or less.
Contract Balances
As of September 30, 2026, and December 31, 2025, we had contract balances and unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed in the amounts of $
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
|
|
|
| (Unaudited) |
| ||
Balance, beginning of period |
| $ |
|
| $ |
| ||
Deposits Received |
|
|
|
|
|
| ||
Deposits applied to Revenue |
|
| ( | ) |
|
| ( | ) |
Deferred revenue adjustments, net |
|
|
|
|
|
| ||
Balance, end of period |
| $ |
|
| $ |
| ||
Equity Compensation Expense / 2016 Equity Incentive Plan
We account for equity compensation expense in accordance with FASB ASC 718, “Compensation—Stock Compensation.” Under the provisions of FASB ASC 718, equity compensation expense is estimated at the grant date based on the award’s fair value.
The valuation methodology used to determine the fair value of options and warrants issued as compensation during the period is the Black-Scholes option-pricing model. The Black-Scholes model requires the use of a number of assumptions including volatility of the stock price, the average risk-free interest rate, and the weighted average expected life of the options. Risk–free interest rates are calculated based on continuously compounded risk–free rates for the appropriate term. The expected term of the Company’s warrants has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” warrants. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its common stock, par value $0.01 (the “Common Stock”) and does not intend to pay dividends on its Common Stock in the foreseeable future. The Company has elected to account for forfeitures as they occur.
On July 7, 2017, our shareholders approved the Company's Amended and Restated 2016 Equity Incentive Plan (the "2016 Plan").
On or around January 29, 2026, the 2016 Plan expired in accordance with its terms and has not yet been replaced by a successor equity incentive plan. Awards outstanding as of the expiration date remain subject to the terms of the 2016 Plan and the applicable award agreements; however, no new awards may be granted under the 2016 Plan following its expiration. The Company intends to submit a successor equity incentive plan for shareholder approval at its next annual meeting of shareholders.
For awards of restricted stock units ("RSUs"), fair value is determined based on the closing market price of the Company's Common Stock on the grant date. Compensation expense for RSUs is recognized on a straight-line basis over the requisite service period.
During the nine months ended September 30, 2026 and 2025, respectively, the Company issued
Concentrations of Credit Risk
Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash and cash equivalents. We maintain cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation limit of $
| 14 |
| Table of Contents |
Long-Lived Assets Including Acquired Intangible Assets
We assess long-lived assets for potential impairments at the end of each year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the asset. In evaluating long-lived assets for impairment, we measure recoverability of these assets by comparing the carrying amounts to the future undiscounted cash flows the assets are expected to generate. If our long-lived assets are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair market value. We base the calculations of the estimated fair value of our long-lived assets on the income approach. For the income approach, we use an internally developed discounted cash flow model that includes, among others, the following assumptions: projections of revenues and expenses and related cash flows based on assumed long-term growth rates and demand trends; expected future investments to grow new units; and estimated discount rates. We base these assumptions on our historical data and experience, industry projections, micro and macro general economic condition projections, and our expectations. We had no long-lived asset impairment charges for the three and nine months ended September 30, 2026 and 2025.
Advertising and Promotional Expenses
Advertising and promotional costs are expensed in the period they are incurred. For the three and nine months ended September 30, 2026, advertising and promotional expenses included in selling expenses were approximately $
Research and Development Expenses
Research and development expenses are expensed in the period they are incurred. For the three and nine months ended September 30, 2026, research and development expenses were approximately $
Business Segments
Pursuant to the guidance in ASC 280, we currently have one reportable business segment due to the fact that we derive our revenue primarily from one product in which 1) The business activities are homogenous in nature, 2) The entire operation faces similar market conditions and risks, 3) There is a high degree of integration in its operations, 4) Internal evaluations of financial results are conducted on a consolidated basis. A breakdown of revenue is presented in “Revenue Recognition” in Note 2 above. See Note 15, Segment Reporting for more details.
Going Concern
For the nine months ended September 30, 2026 and 2025, our net loss was approximately $
Management's Plan to Address Going Concern
Equity Line of Credit and Shelf Registration Statement
In November 2025, we entered into a $
Through September 30, 2026, the Company issued shares under the ELOC representing aggregate gross proceeds of approximately $
Of the net proceeds, approximately $
Approximately $
| 15 |
| Table of Contents |
Capital Markets Access
Our effective Form S-3 shelf registration statement provides a registered platform to raise up to $
Convertible Note Management
As of September 30, 2026, we had $
Pipeline Conversion to Revenue
The Company’s current total sales pipeline is approximately $
As of September 30, 2026, sales backlog totaled approximately $
Cost Management
We reduced total operating expenses by $
Customer Deposit Policy
Our customer deposit policy, implemented during 2025, requires deposits on equipment orders ahead of fulfilment. This policy reduces working capital exposure and is expected to generate incremental operating cash flow benefits in 2026 as it becomes fully embedded across our order intake process.
While management believes the actions described above provide a reasonable basis to address the going concern conditions, there can be no assurance that we will successfully implement this plan, that our pipeline will convert to revenue on the anticipated timeline, or that additional capital will be available on terms acceptable to us. If we are unable to execute this plan, we may be required to delay, reduce, or eliminate certain operations, which could materially adversely affect our business, financial condition, and results of operations.
Recent Accounting Standards
Recently adopted accounting standards
In November 2024, the Financial Accounting Standards Board issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments. This update clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions or debt extinguishments. The Company adopted ASU 2024-04 effective January 1, 2026, using the prospective transition method. Adoption did not have a material impact on the Company’s consolidated financial statements.
In July 2025, FASB issued Accounting Standards Update (“ASU”) No. 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendments in this update provide a practical expedient permitting an entity to assume that conditions at the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current classified accounts receivable and contract assets. This update is effective for annual periods beginning after December 15, 2025, including interim periods within those fiscal years. Adoption of this ASU can be applied prospectively for reporting periods after its effective date. We adopted ASU 2025-05 in the first quarter of 2026 on a prospective basis and did not elect the practical expedient. The adoption of this ASU did not have a material impact on the Company's consolidated financial statements or on the allowance for credit losses as of September 30, 2026.
Recently issued accounting standards not yet adopted
In November 2024, FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40). In January 2025, ASU No. 2025-01 was issued to clarify the effective date for all public business entities. The ASU requires the disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation, and amortization, within relevant income statement captions. This ASU also requires disclosure of the total amount of selling expenses along with the definition of selling expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU can either be applied prospectively to consolidated financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the consolidated financial statements. Early adoption is also permitted. This ASU will likely result in the required additional disclosures being included in our consolidated financial statements once adopted. We are currently evaluating the provisions of this ASU.
In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The ASU clarifies interim disclosure requirements and the applicability of Topic 270. The objective of the amendments is to provide further clarity about the current interim disclosure requirements. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Adoption of this ASU can be applied either a prospective or a retrospective approach. Early adoption is permitted. We are currently evaluating the provisions of this ASU and do not expect this ASU to have a material impact on our consolidated financial statements.
In December 2025, the FASB issued ASU No. 2025-12, Codification Improvements. The ASU addresses thirty-three items, representing the changes to the Codification that (1) clarify, (2) correct errors, or (3) make minor improvements. Generally, the amendments in this Update are not intended to result in significant changes for most entities. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2026. The adoption method of this ASU may vary, on an issue-by-issue basis. Early adoption is permitted. We are currently evaluating the provisions of this ASU and do not expect this ASU to have a material impact on our consolidated financial statements.
| 16 |
| Table of Contents |
NOTE 3. INVENTORIES
Inventories consist of the following:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| (Unaudited) |
|
|
|
| ||
Finished goods |
| $ |
|
| $ |
| ||
Raw materials & work-in-process |
|
|
|
|
|
| ||
Inventory reserve |
|
| ( | ) |
|
| ( | ) |
Total |
| $ |
|
| $ |
| ||
The movements of inventory reserve were as follows:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| (Unaudited) |
|
|
|
| ||
Beginning reserve |
| $ |
|
| $ |
| ||
Additions (provisions) |
|
|
|
|
|
| ||
Write-offs / disposals |
|
|
|
|
| ( | ) | |
Ending reserve |
| $ |
|
| $ |
| ||
The Company maintains an inventory reserve for excess, slow-moving, and obsolete inventory based on historical usage, forecasted demand, inventory aging, product life cycle considerations, and other relevant factors. As of September 30, 2026 and December 31, 2025, our recorded reserve for obsolete inventory was $
Management evaluates the adequacy of the inventory reserve at each reporting date based on the composition and condition of inventory then on hand, including actual sales and usage trends, inventory aging, forecasted demand, and product life cycle considerations. Based on the information available as of September 30, 2026, management believes the recorded reserve represents a reasonable estimate of the amount necessary to reflect excess, slow-moving, and obsolete inventory. The reserve may therefore change in future periods as the underlying inventory is sold, consumed, or otherwise disposed of, or as management's assessment of the inventory population and expected realizability changes, subject to the applicable requirements of ASC 330 and SAB Topic 5.BB. If actual demand for our products differs materially from our forecasts, or if future changes in our product offerings render existing inventory obsolete, additional write-downs may be required.
| 17 |
| Table of Contents |
NOTE 4. VENDOR DEPOSITS
At September 30, 2026, and December 31, 2025, we maintained vendor deposits of $
NOTE 5. PROPERTY AND EQUIPMENT
Property and equipment consist of the following at:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| (Unaudited) |
|
|
|
| ||
Furniture and fixtures |
| $ |
|
| $ |
| ||
Equipment |
|
|
|
|
|
| ||
Vehicles |
|
|
|
|
|
| ||
Computer and software |
|
|
|
|
|
| ||
Leasehold improvements |
|
|
|
|
|
| ||
Tenant improvement allowance |
|
|
|
|
|
| ||
Total Property and Equipment |
| $ |
|
| $ |
| ||
Less: Accumulated Depreciation |
|
|
|
|
|
| ||
Property and equipment, net |
| $ |
|
| $ |
| ||
For the three and nine months ended September 30, 2026, depreciation was $
NOTE 6. INTANGIBLE ASSETS
Intangible assets consist of patents and trademarks related to our Binary Ionization Technology. We amortize the patents over the estimated remaining lives of the related patents. The trademarks have an indefinite life. Amortization expense was $
|
| September 30, |
|
| December 31, |
| ||
|
| 2026 |
|
| 2025 |
| ||
|
| (Unaudited) |
|
|
| |||
Definite life intangible assets consist of the following: |
|
|
|
|
|
| ||
Intellectual property and patents |
| $ |
|
| $ |
| ||
Less: accumulated amortization |
|
|
|
|
|
| ||
Patents, net |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
Indefinite life intangible assets consist of the following: |
|
|
|
|
|
|
|
|
Trademarks |
|
|
|
|
|
| ||
Total intangible assets, net |
| $ |
|
| $ |
| ||
| 18 |
| Table of Contents |
Approximate future amortization is as follows (rounded to nearest thousand):
Years Ended December 31: |
| Amount |
| |
2026 (October – December) |
| $ |
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 |
|
|
| |
2030 |
|
|
| |
2031 |
|
|
| |
Thereafter |
|
|
| |
Total |
| $ |
| |
The following table recaps the depreciation and amortization expense above, as reported in the condensed consolidated statement of operations:
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
Depreciation expense (Note 5) |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Amortization expense (Note 6) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total depreciation and amortization |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
NOTE 7. LEASES
In April 2018, we entered into a
The balances for our operating lease where we are the lessee are presented as follows within our condensed consolidated balance sheet:
|
| As of September 30, |
|
| As of December 31, |
| ||
|
| 2026 |
|
| 2025 |
| ||
|
| (Unaudited) |
|
|
| |||
Assets: |
|
|
|
|
|
| ||
Operating lease right-of-use asset |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
Liabilities: |
|
|
|
|
|
|
|
|
Current portion of long-term operating lease |
| $ |
|
| $ |
| ||
Long-term operating lease, net of current portion |
|
|
|
|
|
| ||
Total right of use liability |
| $ |
|
| $ |
| ||
| 19 |
| Table of Contents |
The components of lease expense are as follows and are included within general and administrative expense on our condensed consolidated statement of operations.
|
| For the three months ended |
|
| For the nine months ended |
| ||||||||||
|
| September 30, (Unaudited) |
|
| September 30, (Unaudited) |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
Operating lease expense |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Supplemental cash flow information related to leases where we are the lessee is as follows:
|
| For the three months ended |
|
| For the nine months ended |
| ||||||||||
|
| September 30, (Unaudited) |
|
| September 30, (Unaudited) |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
Cash paid for amounts included in the measurement of lease liabilities |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Other information related to leases where we are the lessee is as follows:
|
| As of September 30, |
|
| As of December 31, |
| ||
|
| 2026 |
|
| 2025 |
| ||
|
| (Unaudited) |
|
|
| |||
Weighted-average remaining lease term: |
|
|
|
|
|
| ||
Operating leases |
|
|
|
|
|
| ||
Discount rate: |
|
|
|
|
|
|
|
|
Operating leases |
|
| % |
|
| % | ||
As of September 30, 2026, the maturities of our operating lease liability are as follows:
Years ended December 31: |
| Operating Lease |
| |
2026 (October – December) |
| $ |
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 (lease expiration) |
|
|
| |
Total minimum lease payments |
|
|
| |
Less: interest |
|
|
| |
Imputed value of lease obligations |
|
|
| |
Less: current portion |
|
|
| |
Long-term portion of lease obligations |
| $ |
| |
NOTE 8. CONVERTIBLE DEBT
As of September 30, 2026, the Company had two series of convertible promissory notes outstanding, issued under separate Securities Purchase Agreements in 2023 and 2025, with aggregate outstanding principal of $
| 20 |
| Table of Contents |
Convertible notes consisted of the following:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
|
| (Unaudited) |
|
|
|
| ||
2023 Notes |
| $ |
|
| $ |
| ||
2025 Notes |
|
|
|
|
|
| ||
Total convertible notes |
| $ |
|
| $ |
| ||
Less: debt discount |
|
| ( | ) |
|
| ( | ) |
Accumulated amortization |
|
|
|
|
|
| ||
Debt discount, net |
|
| ( | ) |
|
| ( | ) |
Convertible notes, net |
| $ |
|
| $ |
| ||
2023 Notes
$100,000 outstanding as of September 30, 2026
During 2023, we entered into a Securities Purchase Agreement (the “2023 SPA”) with certain accredited investors (the “Investors”) to sell, in a private placement, up to $
The 2023 Notes mature on the fifth anniversary of their issuance dates, in 2028, and bear simple interest at 12% per annum, payable in equal monthly installments. They are unsecured and senior to other indebtedness, subject to certain exceptions.
We may require conversion at the then-applicable conversion price at any time after 90 days from issuance if the Common Stock closes at or above $
2023 Note Amendment & Conversion
On August 12, 2026, the Company entered into an Omnibus Amendment to Convertible Promissory Notes (the “Amendment”) with certain holders of the 2023 Notes, aggregating $
The Company evaluated the Amendment under ASC 470-50 and concluded it was a substantial modification, because the change in the fair value of the embedded conversion option immediately before and after the Amendment exceeded 10% of the carrying amount of the original notes. Accordingly, the amended notes were accounted for as an extinguishment of the existing debt and were recorded at fair value as of August 12, 2026. The fair value of the amended notes, representing $
The fair value of the amended notes was measured on a nonrecurring basis and classified within Level 3 of the fair value hierarchy. The fair value was estimated with the assistance of a third-party valuation specialist using a Monte Carlo simulation. Significant inputs as of the August 12, 2026 valuation date included stock price: $
During the three months ended September 30, 2026, holders of $
2025 Notes
$535,000 outstanding as of September 30, 2026
During 2025, we entered into Securities Purchase Agreements (the “2025 SPA”) with certain accredited investors to sell, in one or more closings, up to $
| 21 |
| Table of Contents |
Registration Rights
In connection with each of the 2023 SPA and the 2025 SPA, we entered into registration rights agreements with the respective Investors pursuant to which we agreed to register for resale the shares of Common Stock issuable upon conversion of the respective 2023 Notes and 2025 Notes. We filed a resale registration statement on Form S-3 covering the shares issuable upon conversion of the Notes issued pursuant to the 2023 SPA. As of September 30, 2026, we have not filed a resale registration statement covering the shares issuable upon conversion of the Notes issued pursuant to the 2025 SPA. We are evaluating the timing and method of fulfilling our registration obligations under the registration rights agreement entered into in connection with the 2025 SPA. Failure to satisfy our registration obligations within the timeframes specified in the respective registration rights agreements could result in the payment of liquidated damages or other penalties to the Investors, the amount of which we are unable to estimate at this time.
Debt discount and Interest Expense
Debt discount costs are amortized to interest expense on a straight-line basis over the life of the notes. The unamortized debt discount on the amended notes that were subsequently converted was derecognized on August 12, 2026 in connection with the extinguishment described above, and no further amortization was recorded on those notes. The remaining unamortized costs relate to the balance of notes still outstanding and will be amortized over their remaining terms (2028 and 2030, respectively).
Annual cash interest at
Interest expense consisted of the following:
|
| For the three months ended |
|
| For the nine months ended |
| ||||||||||
|
| September 30, (Unaudited) |
|
| September 30, (Unaudited) |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
Interest on 2023 Notes |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Interest on 2025 Notes |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Amortization of debt discount |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest expense on convertible debt |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Other interest expense |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total interest expense |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
NOTE 9. SHAREHOLDERS’ EQUITY
Our Board of Directors (the “Board”) may, without further action by our shareholders, from time to time, direct the issuance of any authorized but unissued or unreserved shares of preferred stock in series and at the time of issuance, determine the rights, preferences and limitations of each series. The holders of such preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding up by us before any payment is made to the holders of our common stock. Furthermore, the Board could issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of our common stock.
Reverse Stock Split
On July 17, 2026, the Company filed Articles of Amendment to its Restated Articles of Incorporation with the Secretary of State of the State of Florida to effect a 1-for-3 Reverse Stock Split of its Common Stock and Series A Preferred Stock, effective July 20, 2026. In connection with the Reverse Stock Split, every three shares of issued and outstanding Common Stock and Series A Preferred Stock were automatically combined into one share of the respective class of stock, without any change in the par value per share. The Reverse Stock Split did not change the number of authorized shares of Common Stock or Series A Preferred Stock. No fractional shares were issued in connection with the Reverse Stock Split, and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share.
New CUSIP and Impact on Outstanding Options and Warrants
Our Common Stock continues to trade on The Nasdaq Capital Market under the symbol "TOMZ," under a new CUSIP number, 890023302. The Reverse Stock Split also effected a proportionate reduction in the number of shares of Common Stock issuable upon exercise of our outstanding options and warrants, with a corresponding adjustment to each instrument's exercise price.
| 22 |
| Table of Contents |
Retroactive Adjustment
All share and per share amounts (including shares outstanding, weighted average shares, and earnings per share) presented in the accompanying condensed consolidated financial statements have been retroactively restated for all periods presented, in accordance with ASC 260, Earnings Per Share.
This retroactive treatment has also been applied to the presentation of Common Stock, Preferred Stock, and Additional Paid-in Capital as of September 30, 2026 and December 31, 2025, with the par value of the retired shares reclassified to Additional Paid-in Capital as if the Reverse Stock Split had occurred at the beginning of the earliest period presented. The Reverse Stock Split was legally effected on July 20, 2026; accordingly, the corresponding ledger reclassification entry was recorded in the Company's accounting records in the third quarter of 2026.
Common & Preferred Stock
Convertible Series A Preferred Stock
Our authorized Convertible Series A Preferred Stock, $
Convertible Series B Preferred Stock
Our authorized Convertible Series B Preferred Stock, $
Common Stock
In May 2025, we issued
During the three months ended March 31, 2026, we issued
During the three months ended June 30, 2026, we issued
During the three months ended September 30, 2026, we issued
During the three months ended September 30, 2026, we accrued for
Equity Purchase Agreement — Hudson Global Ventures, LLC
On November 5, 2025, the Company entered into an Equity Purchase Agreement (the "Purchase Agreement") with Hudson Global Ventures, LLC ("Hudson Global"), pursuant to which the Company has the right, but not the obligation, to sell to Hudson Global up to $
| 23 |
| Table of Contents |
Exchange Cap Waiver
ELOC Purchase Agreement – Exchange Cap Waiver On June 4, 2026, in accordance with Section 607.0704 of the Florida Business Corporation Act, shareholders holding a majority of the Company's outstanding voting power approved, by written consent, the issuance of shares of Common Stock to Hudson under the ELOC in excess of 4,043,018 shares (the "Exchange Cap"), representing 19.99% of the Company's outstanding Common Stock as of the date the ELOC Purchase Agreement was executed. This approval permits the Company to direct sales of Purchase Shares to Hudson Global under the $20,000,000 ELOC Purchase Agreement in excess of the Exchange Cap in compliance with Nasdaq Listing Rule 5635(d). Pursuant to Rule 14c-2 of the Exchange Act, this corporate action became effective on June 25, 2026, twenty calendar days after the Company's Information Statement on Schedule 14C was first mailed to shareholders of record on June 5, 2026.
During the nine months ended September 30, 2026, pursuant to the ELOC, we issued an aggregate of
Share and per-share amounts have been retroactively adjusted to reflect the Company's
Stock Options, Warrants and RSUs
Stock Options
Stock option activity for the nine months ended September 30, 2026 is summarized in the following table:
|
| For the nine months ended September 30, 2026 (Unaudited) |
| |||||
|
| Number of Options |
|
| Weighted Average Exercise Price |
| ||
Outstanding, beginning of period |
|
|
|
| $ |
| ||
Granted |
|
| - |
|
|
|
| |
Exercised |
|
| - |
|
|
|
| |
Expired |
|
| ( | ) |
|
|
| |
Outstanding, end of period |
|
|
|
| $ |
| ||
Options outstanding and exercisable by price range as of September 30, 2026 were as follows:
|
| Outstanding Options |
| Exercisable Options | ||||
Exercise Price |
| Number |
| Weighted Average Remaining Contractual Life in Years |
| Number |
| Weighted Average Exercise Price |
$2.13 |
|
|
|
| $ | |||
$2.25 |
|
|
|
| $ | |||
$2.40 |
|
|
|
| $ | |||
$2.55 |
|
|
|
| $ | |||
$3.36 |
|
|
|
| $ | |||
$5.79 |
|
|
|
| $ | |||
|
|
|
|
| $ | |||
| 24 |
| Table of Contents |
Stock Warrants
Stock warrant activity for the nine months ended September 30, 2026 is summarized in the following table:
|
| For the nine months ended September 30, 2026 (Unaudited) |
| |||||
|
| Number of Warrants |
|
| Weighted Average Exercise Price |
| ||
Outstanding, beginning of period |
|
|
|
| $ |
| ||
Granted |
|
| - |
|
|
|
| |
Exercised |
|
| - |
|
|
|
| |
Expired |
|
| ( | ) |
|
| ( | ) |
Outstanding, end of period |
|
|
|
| $ |
| ||
Warrants outstanding and exercisable by price range as of September 30, 2026 were as follows:
|
| Outstanding Warrants |
| Exercisable Warrants | ||||
Exercise Price |
| Number |
| Weighted Average Remaining Contractual Life in Years |
| Number |
| Weighted Average Exercise Price |
$1.92 |
|
|
|
| $ | |||
$2.40 |
|
|
|
| $ | |||
$2.88 |
|
|
|
| $ | |||
$12.00 |
|
|
|
| $ | |||
$20.85 |
|
|
|
| $ | |||
|
|
|
|
| $ | |||
There were no unvested warrants outstanding as of September 30, 2026.
RSU’s Outstanding
There were no RSU’s outstanding as of September 30, 2026.
NOTE 10. COMMITMENTS AND CONTINGENCIES
Legal Contingencies
We may become a party to litigation in the normal course of business. In the opinion of management, there are no legal matters involving us that would have a material adverse effect upon our financial condition, results of operations or cash flows. In addition, from time to time, we may have to file claims against parties that infringe on our intellectual property.
Product Liability
As of September 30, 2026, and December 31, 2025, there were no claims against us for product liability.
| 25 |
| Table of Contents |
NOTE 11. CONTRACTS AND AGREEMENTS
Director Compensation
During the nine months ended September 30, 2026, director agreements for non-employee members of our Board consisted of an annual cash fee of $
During the nine months ended September 30, 2025, our previous director agreements for non-employee members of our Board consisted of an annual cash fee of $
Agreement for the Purchase and Sale of Future Receipts
Effective November 18, 2025, the Company entered into an agreement with Agile Capital Funding, LLC ("Agile") accounted for as debt under ASC 470-10-25. As of September 30, 2026, the debt was fully repaid, compared to an outstanding gross remaining balance of $
Agreement and Plan of Merger with Carbonium Core, Inc.
On June 28, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Carbonium Core, Inc. (“Carbonium”) and TOMZ Merger Sub, Inc., a wholly owned subsidiary of the Company. On September 15, 2026, the Company and Carbonium mutually agreed to terminate the Merger Agreement. No termination fee was payable by the Company, each party is responsible for its own fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby, and the parties released each other from all claims and liabilities related to the transaction documents.
NOTE 12. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following at:
|
| As of September 30, |
|
| As of December 31, |
| ||
|
| 2026 |
|
| 2025 |
| ||
|
| (Unaudited) |
|
|
|
| ||
Commissions |
| $ |
|
| $ |
| ||
Payroll and related costs (1) |
|
|
|
|
|
| ||
Sales tax payable |
|
|
|
|
|
| ||
Other accrued expenses and other current liabilities |
|
|
|
|
|
| ||
|
| $ |
|
| $ |
| ||
(1) Included within payroll and related costs is the accrual of earned but unpaid compensation to certain executive officers. As a cash conservation measure, certain members of executive management have not been paid their earned compensation in cash during the year. These obligations are fully accrued in accordance with ASC 710 and remain payable in accordance with the terms of the applicable employment arrangements. The Company intends to satisfy these obligations as operating cash flow permits. For further information regarding the compensation arrangements with the Company's named executive officers, including the portion of salary earned but not paid in cash during fiscal 2025, see the Summary Compensation Table and related footnotes in Part III, Item 11 of the Company’s Form 10-K, as filed on March 31, 2026.
| 26 |
| Table of Contents |
NOTE 13. INCOME TAXES
For the three and nine months ended September 30, 2026, and 2025, our provision for income tax was $
The Company previously adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, for the fiscal year ended December 31, 2025 on a prospective basis as of January 1, 2025. The standard affects annual disclosures only, and its adoption did not have a material impact on the Company’s condensed consolidated financial statements. For full disclosures regarding our Net Operating Loss carryforwards and rate reconciliations, please refer to our 2025 Form 10-K, as filed on March 31, 2026.
On July 4, 2025, the U.S. H.R.1, an act to provide for reconciliation pursuant to title II of H. Con. Res. 14. (the “OBBBA”) was enacted. The OBBBA introduces multiple tax law and other legislative changes, including modifications to income tax provisions such as domestic research and development expenses, capital expenditures, and U.S. taxation of international earnings; the repeal or acceleration of the sunset of certain tax credits under the 2022 Inflation Reduction Act and elimination of certain penalties for violations of certain regulatory credit programs. We have recognized the effects of the OBBBA provisions in our financial results to the extent they are applicable to the year ended December 31, 2025. We will continue to evaluate the impact of these provisions on our 2026 and subsequent consolidated financial statements.
NOTE 14. CUSTOMER CONCENTRATION
The Company monitors customer concentration by identifying customers whose accounts receivable balances individually represent
Accounts Receivable Concentration
As of September 30, 2026, Customer A and Customer B accounted for approximately
Revenue Concentration
For the three months ended September 30, 2026, Customer A and Customer B accounted for approximately
For the nine months ended September 30, 2026, no customers accounted for approximately 10% or more of the Company's revenue. One customer accounted for approximately
The increase in the concentration percentage was mainly due to a distributor that was onboarded during the first half of 2026 and additional CES-related projects undertaken this period.
The Company does not have any long-term purchase commitments with any of its significant customers, and there can be no assurance that these customers will continue to purchase the Company's products and services at historical levels or at all. The loss of, or a significant reduction in purchases by, any one of these customers could have a material adverse effect on the Company's revenue and results of operations. See Item 1A, Risk Factors, from our recently filed Form 10-K for further discussion of risks related to customer concentration and the absence of long-term customer contracts.
NOTE 15. SEGMENT REPORTING
The Company operates and is managed as a single operating and reportable segment pursuant to ASC 280. Our Chief Executive Officer is the chief operating decision maker ("CODM") and is responsible for allocating resources and assessing performance across the organization.
The CODM manages the business and allocates resources on a consolidated basis. In assessing performance and making resource allocation decisions, the CODM regularly reviews consolidated financial information including net revenue, gross profit and operating income (loss), which is the Company’s reported measure of segment profit (loss) under ASC 280. The CODM uses operating income (loss), compared against budget and forecast, to decide how to allocate resources such as inventory purchases, personnel and capital raising activities. The CODM also regularly reviews trends in the significant expense categories included in this measure, which are the categories presented on the face of the condensed consolidated statements of operations: cost of sales, professional fees, depreciation and amortization, selling expenses, research and development, consulting fees, and general and administrative expenses. Other income (expense), net, which is not included in the measure of segment profit (loss), consists of the items presented on the face of the condensed consolidated statements of operations and reconciles operating loss to net loss.
The measure of segment assets is total assets, as reported in the condensed consolidated balance sheets. Other than our cash and cash equivalents, which are reviewed for liquidity management purposes, the CODM does not regularly review asset information at any lower level of the organization for purposes of allocating resources or assessing performance.
The Company derives its revenue primarily from the sale of equipment and services based on its proprietary BIT technology, both domestically and internationally. A disaggregation of revenue is presented in Note 2, Summary of Significant Accounting Policies, under Revenue Recognition.
There have been no changes to the Company's segment structure during the three and nine months ended September 30, 2026. For further information, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026.
NOTE 16. SUBSEQUENT EVENTS
On October 11, 2026, the Board of Directors appointed Mr. Niroshan Srirathan, previously the Company’s Interim Chief Financial Officer, as disclosed on the Company’s current report on Form 8-K filed on May 19, 2026, to the position of permanent Chief Financial Officer, effective immediately.
| 27 |
| Table of Contents |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (this “MD&A”) and other parts of this Quarterly Report on Form 10-Q (“Form 10-Q”) contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Forward-looking statements involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Forward-looking statements are not guaranteeing future performance and the TOMI Environmental Solutions, Inc. (the “Company,” “TOMI,” “we,” and “our”) actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of the Company’s annual report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2026 (the “Annual Report”) under the heading “Risk Factors.” The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.
Unless otherwise stated, all information presented herein is based on the Company’s fiscal calendar, and references to years, quarters, months or periods refer to the Company’s fiscal years ended in December and the associated quarters, months and periods of those fiscal years. Each of the terms the “Company” and “TOMI” as used herein refers collectively to TOMI Environmental Solutions, Inc. unless otherwise stated.
The following MD&A should be read in conjunction with the Annual Report filed with the SEC and the condensed consolidated financial statements and accompanying notes included in Part I, Item 1 of this Form 10-Q.
Quarterly Highlights
Business and Financial Update
Revenue for the third quarter of 2026 was approximately $2.49 million, representing an approximately 24% increase compared with $2.01 million in the third quarter of 2025 and an approximately 11% sequential increase compared with $2.25 million in the second quarter of 2026. For the nine months ended September 30, 2026, the Company recognized revenue of approximately $6.39 million. In addition, the Company generated approximately $1.79 million of sales during 2026 that had not yet been recognized as revenue as of September 30, 2026, bringing total recognized revenue and such unrecognized sales for the year to approximately $8.18 million. Total sales order backlog was approximately $2.5 million as of September 30, 2026, and has since increased to approximately $2.8 million, providing visibility into near-term revenue conversion.
Importantly, the Company returned to positive operating income during the third quarter for the first time since the third quarter of 2024, generating approximately $30,000 of operating income compared with operating losses of approximately $244,000 in the second quarter of 2026 and $626,000 in the first quarter of 2026. The improvement reflects continued revenue growth and operating expense discipline.
Gross margin was approximately 59.0% for the third quarter of 2026, compared with approximately 61.7% in the second quarter of 2026 and 61.2% in the third quarter of 2025. Despite the lower margin percentage, gross profit increased approximately $238,000, or 19%, to approximately $1.47 million from $1.23 million in the third quarter of 2025, reflecting the benefit of higher revenue.
Operating expenses decreased approximately $189,000, or 12%, sequentially to approximately $1.44 million from $1.63 million in the second quarter of 2026, and decreased approximately $113,000, or 7%, compared with the third quarter of 2025. The reductions reflect the Company’s continued focus on operating efficiency and disciplined expense management, primarily through lower general and administrative expenses, partially offset by approximately $276,000 of professional fees during the quarter, including elevated legal costs associated with strategic and financing activities.
Net loss was approximately $189,000 for the third quarter of 2026, including a non-cash loss on extinguishment of convertible debt of approximately $149,000, representing an improvement of approximately 51% compared with a net loss of approximately $382,000 in the second quarter of 2026. Excluding the non-cash extinguishment charge, net loss would have been approximately $40,000, representing an improvement of approximately 90% compared with the second quarter of 2026 and approximately 91% compared with a net loss of approximately $450,000 in the third quarter of 2025.
Non-GAAP Financial Measures
The Company defines non-GAAP net loss as GAAP net loss excluding the non-cash loss on extinguishment of convertible debt. Management believes this measure provides useful supplemental information to investors because the excluded charge resulted from the accounting for the amendment of the Company's convertible notes, did not require the use of cash during the period and is separate from the Company's operating activities. Management uses this supplemental measure, together with GAAP results, to evaluate the Company's period-to-period operating performance and to assess the results of the underlying business without the effect of this financing-related, non-cash charge.
For the three months ended September 30, 2026, GAAP net loss was approximately $189,000 and non-GAAP net loss was approximately $40,000, excluding the approximately $149,000 non-cash loss. For the nine months ended September 30, 2026, GAAP net loss was approximately $1,382,000 and non-GAAP net loss was approximately $1,233,000.
Non-GAAP net loss is supplemental to, and should not be considered in isolation from or as a substitute for, net loss or other financial information prepared in accordance with GAAP. The Company's calculation of non-GAAP net loss may differ from similarly titled measures reported by other companies and therefore may not be directly comparable.
A reconciliation of GAAP net loss to non-GAAP net loss is as follows:
|
| For the Three Months Ended |
|
| For the Nine Months Ended |
| ||||||||||
|
| September 30, 2026 |
|
| September 30, 2025 |
|
| September 30, 2026 |
|
| September 30, 2025 |
| ||||
GAAP net loss |
| $ | (188,986 | ) |
| $ | (450,348 | ) |
| $ | (1,381,931 | ) |
| $ | (1,943,457 | ) |
Non-cash loss on extinguishment of convertible debt |
|
| 149,257 |
|
|
| - |
|
|
| 149,257 |
|
|
| - |
|
Non-GAAP net loss |
| $ | (39,729 | ) |
| $ | (450,348 | ) |
| $ | (1,232,674 | ) |
| $ | (1,943,457 | ) |
The Company also strengthened its balance sheet and liquidity position during the first nine months of 2026. Working capital increased from approximately $1.02 million at December 31, 2025 to approximately $1.95 million at September 30, 2026, while the current ratio improved from approximately 1.32x to 1.49x, reflecting an improvement in the Company’s short-term liquidity position and ability to meet its current obligations. Cash and cash equivalents increased from approximately $88,000 to approximately $195,000 over the same period. Stockholders’ equity increased from approximately $0.59 million to $4.01 million, while the carrying value of convertible note obligations decreased by approximately 80%. Collectively, these developments strengthened the Company’s liquidity, capitalization and overall financial position entering the fourth quarter.
The Company’s current total sales pipeline is approximately $35 million with 25% of the pipeline in advanced stages, which management believes provides a meaningful source of future revenue growth. Our integrated project pipeline for SteraMist Integrated Systems ("SIS"), Hybrid, and Custom Engineered Systems ("CES") continues to increase and is a major component for the increase in our overall sales pipeline. These opportunities represent potential future revenue and are not committed orders or guarantees of future performance.
| 28 |
| Table of Contents |
In the third quarter of 2026, the second-quarter trends continued across BIT Solution sales, mobile equipment, single applicators—where our patented iHP intellectual property resides—and support services, including qualification, acceptance testing, and training. What changed in the quarter was mobile equipment. Those results improved sharply and helped even out contribution across our revenue streams year to date.
Customers continued to expand deployment of our patented cold plasma technology. The applicator remains the component that enables iHP, whether paired with a mobile system or installed in a permanent or semi-permanent configuration.
We began emphasizing this strategy less than two years ago as an extension of our consumable-driven model. The applicator functions as a second “razor” in a razor-and-blade framework: a longer replacement cycle than BIT Solution, but a shorter sales cycle than full capital equipment. It generates revenue and margin now while supporting recurring BIT Solution demand. The third-quarter improvement in mobile equipment is what brought these streams into closer balance year to date.
Mobile equipment sales in the third quarter were driven by our existing customer base. At the end of the third quarter of 2026, mobile sales including our SteraMist Integration System StandAlone (SIS-SA) was up 47.5% for the year when compared to the full 2025 year. Many of those sales came from customers expanding within current facilities or into additional locations. Some added the same equipment already in use; others moved to our SteraMist Integration System (SIS) platform or our Environment System foggers. These results were achieved despite a reduced marketing budget, and the same pattern held in Life Sciences, Commercial, and Food Safety. We expect to continue generating additional business from these customers and other existing customers in the fourth quarter, which, together with new customers, we expect to support higher revenue in these streams.
Our intellectual property portfolio is a key strategic asset supporting our global market position. We hold or have pending over 45 utility or design patents worldwide, protecting both the methods and systems underlying our SteraMist® BIT™ platform, with U.S. patents extending through 2038. Recent additions include patents for backpack decontamination units, mobile carts, and enhanced applicator technology in the United States, alongside protections in diverse other countries including Singapore, Korea, Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia, Sweden, Brazil, Mexico, United Kingdom, Israel, Japan and Australia. We continue to advance protections for further inventive enhancements to our technologies, including computer-automated biosecurity systems for decontamination of buildings in the United States, and Europe; enhanced applicator technologies in the United States, Europe, China, Australia, and Korea; and food decontamination technology in the United States. In particular, we have recently obtained a Japanese patent protecting our inventive computer-automated biosecurity systems, as well as an allowance for a patent in the United States covering the same biosecurity technology; and we have also obtained allowances for patents protecting our enhanced applicator technologies and systems in the United States. Most recently, in the United States we have obtained a US patent covering the application of our aerosolized ionized hydrogen peroxide technology to decontamination of small interior spaces, which has broad application to decontamination of built environments. We have also obtained allowance for a new US patent for our rotating applicator unit. We are continuing to file new applications this year both in the United States and internationally for inventive technologies that lead in the biosecurity and decontamination fields.
We hold more than 30 design patents for decontamination devices, covering applicators, chambers, carts, and surface-mounted systems, across major global markets including the United States, China, Japan, Korea, and the United Kingdom. We recently obtained allowance for our ceiling-mounted applicator technology. In addition, we maintain over 200 trademarks registered or pending in multiple classes across the globe, covering chemical formulations, sterilization equipment, services, and training.
During the quarter, we continued to strengthen our registration portfolio and continued progress toward NSF certification for Biosafety Cabinet decontamination. In the Food Safety market, we have been granted a new unconditional registration for AgriMist, TOMI’s fourth Environmental Protection Agency (EPA) label registration. This expanded label significantly broadens our approved use sites to include a wide range of food safety applications.
Food Safety was a regulatory focus in the third quarter, not the driver of the quarter’s results. We engaged Josh Hasty, Ph.D., CEO of FH Services, LLC, to support work in meat and ready-to-eat applications. Dr. Hasty previously served as Director of Food Safety & Quality Assurance and Director of R&D at Tyson Foods’ Ingredient Solutions Group and as a technical lead on Cargill’s McDonald’s beef program. The engagement adds industry expertise.
On October 15, 2026, we announced an independent laboratory study reporting average reductions greater than 7 log on flat test surfaces and greater than 3 log on threaded parts under the tested conditions for Listeria monocytogenes in biofilm. Listeria monocytogenes is a foodborne pathogen and a recurring cause of costly product recalls. In processing facilities, it often forms biofilm, a protective layer that allows it to adhere to surfaces and withstand routine sanitation, enabling contamination to persist and driving demand for more effective control methods. Food safety is one of TOMI's priority growth markets, and these results give the sales team and partners independent laboratory data to bring to food processors.
Work in dairy and infant formula continued with Nestlé and Danone while we pursue the applicable international registrations and Food Contact Notifications. We also continued related work with Abbott Nutrition and received initial testing data during the quarter. Certain Abbott domestic facilities are seeking to use iHP. Commercial use depends on satisfactory completion of that testing and on obtaining the required FDA authorization, which we have not received.
For a proposed direct-food use, hydrogen peroxide may be used under 21 C.F.R. § 173.356 only under the regulation’s specified conditions. The pathway for the complete formulation depends on the intended use, technical effect, and expected residue and exposure. The current regulatory record does not support a no-detectable-residue claim for poultry use.
For use in an FSIS-inspected establishment, the applicable requirements depend on whether SteraMist contacts poultry directly, food-contact equipment, or only the environment. TOMI will determine whether an FSIS inquiry or New Technology notification is appropriate once the intended use is defined.
In the healthcare sector, we have seen growing adoption of iHP technology by Special Pathogen Units throughout the first half of 2026, with additional opportunities developing for the second half of the year. These units, which manage high-consequence infectious diseases, require rapid, validated, and comprehensive decontamination of rooms, equipment, and personal protective equipment.
| 29 |
| Table of Contents |
TOMI continues to expand its presence in the defense sector, having recently received approvals from defense contractors in Korea and defense agencies in Canada. While confidentiality agreements limit the disclosure of specific details, these relationships represent multi-year engagements supported by detailed strategic plans and have significant long-term potential.
In addition, TOMI has authorized a local representative to distribute for the Defense Logistics Agency (DLA), which manages the global defense supply chain for the U.S. military services and allied partners. This partnership, established in the second quarter, is expected to streamline and accelerate government procurement of SteraMist iHP technology.
SteraMist was named Disinfection and Decontamination Products Company of the Year for 2026 by Medical Tech Outlook, representing a back-to-back global award for the brand.
Agreement and Plan of Merger with Carbonium Core, Inc.
On September 15, 2026, the Company and Carbonium mutually agreed to terminate the Merger Agreement. No termination fee was payable by the Company, and each party is responsible for its own fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby. The parties also released each other from all claims and liabilities related to the transaction documents.
For additional information regarding the termination of the Merger Agreement, refer to the Company’s Current Report on Form 8-K filed with the SEC on September 21, 2026.
Reverse Stock Split
On July 17, 2026, the Company filed Articles of Amendment to its Restated Articles of Incorporation with the Secretary of State of the State of Florida to effect a 1-for-3 Reverse Stock Split of its Common Stock and Series A Preferred Stock, effective July 20, 2026. In connection with the Reverse Stock Split, every three shares of issued and outstanding Common Stock and Series A Preferred Stock were automatically combined into one share of the respective class of stock, without any change in the par value per share. The Reverse Stock Split did not change the number of authorized shares of Common Stock or Series A Preferred Stock. No fractional shares were issued in connection with the Reverse Stock Split, and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share.
The Reverse Stock Split also resulted in proportionate adjustments to the number of shares underlying the Company’s outstanding stock options, warrants and restricted stock units, as applicable, and corresponding adjustments to the exercise prices of outstanding options and warrants. All share and per-share amounts, including options, warrants, conversion prices and loss per share, have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented, unless otherwise indicated. See Note 9, Shareholders’ Equity, for additional information.
Business Highlights and Recent Events
| · | On July 29, 2026, TOMI reaffirmed its expectation to achieve revenue of at least $12 million for fiscal 2026 and confirmed a $35 million sales pipeline with approximately $8.6 million in advanced stages. The release also cited over $6.2 million in booked and expected orders, continued European regulatory expansion, approvals from defense contractors in Korea and defense agencies in Canada, and a planned partnership with the U.S. Defense Logistics Agency. |
|
|
|
| · | On August 3, 2026, the U.S. Environmental Protection Agency granted a new unconditional registration for SteraMist® (BIT®) – AgriMist (EPA Reg. No. 90150-4), expanding labeled use sites to include post-harvest food safety applications, cannabis and hemp cultivation, and greenhouse and hydroponic agriculture, including post-harvest treatment of raw agricultural commodities. |
|
|
|
| · | On August 17, 2026, TOMI’s Binary Ionization Technology received formal approval in Ireland under the European Union’s Biocidal Products Regulation, bringing approvals to 11 European markets. |
|
|
|
| · | On September 17, 2026, TOMI reported approximately $2.3 million in SteraMist iHP enclosure purchase orders year-to-date, exceeding the approximately $1.6 million in comparable enclosure orders over the prior four years combined. |
|
|
|
| · | On September 18, 2026, TOMI reported year-to-date SteraMist iHP service and support sales of approximately $1.7 million, surpassing the approximately $1.3 million recorded in each of full-year 2024 and full-year 2025. |
|
|
|
| · | On September 21, 2026, TOMI announced the mutual termination of its definitive merger agreement with Carbonium Core, Inc. The Board of Directors approved the termination on September 20, 2026, and both parties concluded the business combination was no longer in the best strategic or financial interest of their respective stakeholders. Each party will bear its own fees and expenses related to the merger agreement. |
|
|
|
| · | On September 29, 2026, TOMI announced modular integration concepts for its SteraMist iHP platform targeting autonomous vehicle fleets, drone platforms and robotic systems. |
|
|
|
| · | On September 30, 2026, TOMI announced that Project MEND, a San Antonio nonprofit that refurbishes and redistributes used medical equipment, implemented SteraMist iHP to disinfect reusable durable medical equipment before it is redistributed. |
| 30 |
| Table of Contents |
Post-Quarter Developments:
| · | On October 1, 2026, TOMI announced the expansion of SteraMist iHP into India’s pharmaceutical market through its distribution partner, STS Technocrat (India) Pvt. Ltd., which recently signed a pharmaceutical company customer and is working with TOMI on a turnkey, fully integrated iHP enclosure. |
|
|
|
| · | On October 7, 2026, TOMI confirmed its readiness to support biosecurity preparedness and front-line response worldwide, following reports of a suspected outbreak at a research institute in Russia. |
|
|
|
| · | On October 8, 2026, TOMI reported preliminary third quarter 2026 revenue of approximately $2.5 million, an increase of 24% over the third quarter of 2025 and 11% over the second quarter of 2026, with an open order book of $2.5 million at quarter-end and $1.7 million already booked for the fourth quarter. Management stated it remains on track for its $12 million revenue target for 2026 and expects the fourth quarter to be profitable. |
|
|
|
| · | On October 15, 2026, TOMI reported independent laboratory results showing SteraMist iHP reduced Listeria monocytogenes biofilm on flat surfaces by an average of more than 7 log, with a reduction of more than 3 log on hard-to-reach equipment parts. |
|
|
|
| · | On October 29, 2026, we announced a three-phase order of approximately $402,000 from Zeyco, a Mexican pharmaceutical manufacturer, for a multi-line SteraMist Hybrid System. |
|
|
|
| · | On November 4, 2026, we announced a recurring BIT Solution purchase agreement with an existing global eye health customer. Combined revenue from two of its facilities is approximately $750,000, including additional third quarter 2026 orders. |
The following overview summarizes key factors affecting our financial performance for the three and nine months ended September 30, 2026 compared to the Consolidated Balance Sheet as of December 31, 2025 and should be read in conjunction with the selected financial metrics presented below.
Financial Operations Overview (in thousands) |
| September 30, 2026 |
|
| December 31, 2025 |
|
| Change |
| |||
Cash and cash equivalents |
| $ | 195 |
|
| $ | 88 |
|
| $ | 107 |
|
Accounts receivable, net |
| $ | 2,593 |
|
| $ | 689 |
|
| $ | 1,904 |
|
Inventories, net (Note 3) |
| $ | 2,381 |
|
| $ | 2,926 |
|
| $ | (545 | ) |
Working capital |
| $ | 1,948 |
|
| $ | 1,024 |
|
| $ | 924 |
|
Total shareholders’ equity |
| $ | 4,013 |
|
| $ | 589 |
|
| $ | 3,424 |
|
Total debt (convertible notes) |
| $ | 592 |
|
| $ | 2,912 |
|
| $ | (2,320 | ) |
The following tables summarize selected financial metrics based on the Company’s Consolidated Statement of Operations for the three and nine months ended September 30, 2026 compared to September 30, 2025 and provide a high-level overview of the Company’s operating performance.
|
| For the Three Months Ended |
|
|
| |||||||
Key financial metrics (in thousands, except per share data) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
| |||
Revenue |
| $ | 2,493 |
|
| $ | 2,012 |
|
| $ | 481 |
|
Gross profit |
| $ | 1,470 |
|
| $ | 1,232 |
|
| $ | 238 |
|
Operating expenses |
| $ | 1,440 |
|
| $ | 1,553 |
|
| $ | (113 | ) |
Income (Loss) from operations |
| $ | 30 |
|
| $ | (321 | ) |
| $ | 351 |
|
Net loss |
| $ | (189 | ) |
| $ | (450 | ) |
| $ | 261 |
|
Basic and diluted loss per share |
| $ | (0.02 | ) |
| $ | (0.07 | ) |
| $ | 0.05 |
|
|
| For the Nine Months Ended |
|
|
| |||||||
Key financial metrics (in thousands, except per share data) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
| |||
Revenue |
| $ | 6,394 |
|
| $ | 4,619 |
|
| $ | 1,775 |
|
Gross profit |
| $ | 3,687 |
|
| $ | 2,861 |
|
| $ | 826 |
|
Operating expenses |
| $ | 4,527 |
|
| $ | 5,069 |
|
| $ | (542 | ) |
Loss from operations |
| $ | (840 | ) |
| $ | (2,208 | ) |
| $ | 1,368 |
|
Net loss |
| $ | (1,382 | ) |
| $ | (1,943 | ) |
| $ | 562 |
|
Basic and diluted loss per share |
| $ | (0.18 | ) |
| $ | (0.29 | ) |
| $ | 0.11 |
|
| 31 |
| Table of Contents |
The following discussion presents a summary of our results of operations for the three and nine months ended September 30, 2026, and 2025, together with highlights of recent improvements within the Company.
Results of Operations: Strong revenue growth of 24% to $2.49 million for the three months and 38% to $6.39 million for the nine months ended September 30, 2026 was accompanied by improved operating performance. Gross profit increased 19% and 29%, respectively, while operating expenses declined 7% and 11%, respectively. For the third quarter, this resulted in operating income of approximately $30,000, compared with an operating loss of approximately $321,000 in the third quarter of 2025. Below operating income, the Company recognized an approximately $149,000 non-cash loss on extinguishment of convertible debt related to the August 2026 note amendment.
The nine-month improvement was achieved despite the prior-year period including approximately $535,000 of Employee Retention Credit income and the current-year period including an approximately $149,000 non-cash loss on extinguishment of convertible debt. Following the conversion of $2.5 million of the 2023 Notes during the period, we expect annual interest expense to decrease by approximately $300,000. Additionally, general and administrative expenses benefited from a net credit loss benefit of approximately $268,000 for the nine months ended September 30, 2026, compared with credit loss expense of approximately $198,000 in the prior-year period, reflecting improved customer collections and credit performance.
|
| For the Three Months Ended |
|
|
| |||||||
Results of operations (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
| |||
Revenue |
| $ | 2,493 |
|
| $ | 2,012 |
|
| $ | 481 |
|
Cost of sales |
|
| 1,023 |
|
|
| 780 |
|
|
| 243 |
|
Gross profit |
| $ | 1,470 |
|
| $ | 1,232 |
|
| $ | 238 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
| $ | 276 |
|
| $ | 185 |
|
| $ | 91 |
|
Depreciation and amortization |
|
| 48 |
|
|
| 68 |
|
|
| (20 | ) |
Selling expenses |
|
| 197 |
|
|
| 144 |
|
|
| 53 |
|
Research and development |
|
| 42 |
|
|
| 11 |
|
|
| 31 |
|
Consulting fees |
|
| 95 |
|
|
| 73 |
|
|
| 22 |
|
General and administrative |
|
| 782 |
|
|
| 1,072 |
|
|
| (290 | ) |
Total operating expenses |
| $ | 1,440 |
|
| $ | 1,553 |
|
| $ | (113 | ) |
Income (Loss) from operations |
| $ | 30 |
|
| $ | (321 | ) |
| $ | 351 |
|
Other income (expense) |
|
| (219 | ) |
|
| (129 | ) |
|
| (90 | ) |
Provision for income taxes |
|
| - |
|
|
| - |
|
|
| - |
|
Net loss |
| $ | (189 | ) |
| $ | (450 | ) |
| $ | 261 |
|
Basic and diluted loss per share |
|
| (0.02 | ) |
|
| (0.07 | ) |
|
| 0.05 |
|
|
| For the Nine Months Ended |
|
|
| |||||||
Results of operations (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
| |||
Revenue |
| $ | 6,394 |
|
| $ | 4,619 |
|
| $ | 1,775 |
|
Cost of sales |
|
| 2,707 |
|
|
| 1,758 |
|
|
| 949 |
|
Gross profit |
| $ | 3,687 |
|
| $ | 2,861 |
|
| $ | 826 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
| $ | 801 |
|
| $ | 589 |
|
| $ | 212 |
|
Depreciation and amortization |
|
| 151 |
|
|
| 206 |
|
|
| (55 | ) |
Selling expenses |
|
| 617 |
|
|
| 630 |
|
|
| (13 | ) |
Research and development |
|
| 137 |
|
|
| 139 |
|
|
| (2 | ) |
Consulting fees |
|
| 341 |
|
|
| 215 |
|
|
| 126 |
|
General and administrative |
|
| 2,480 |
|
|
| 3,290 |
|
|
| (810 | ) |
Total operating expenses |
| $ | 4,527 |
|
| $ | 5,069 |
|
| $ | (542 | ) |
Loss from operations |
| $ | (840 | ) |
| $ | (2,208 | ) |
| $ | 1,368 |
|
Other income (expense) |
|
| (542 | ) |
|
| 265 |
|
|
| (807 | ) |
Provision for income taxes |
|
| - |
|
|
| - |
|
|
| - |
|
Net loss |
| $ | (1,382 | ) |
| $ | (1,943 | ) |
| $ | 562 |
|
Basic and diluted loss per share |
|
| (0.18 | ) |
|
| (0.29 | ) |
|
| 0.11 |
|
| 32 |
| Table of Contents |
The following discussion describes our improved revenue metrics for the three and nine months ended September 30, 2026 compared to the same periods in 2025 (by total, by type and by geography):
Total Revenue: For the three months ended September 30, 2026, total revenue was $2,493,000 compared to $2,012,000 in the prior period, an increase of $481,000, or 24%. For the nine months ended September 30, 2026, total revenue was $6,394,000 compared to $4,619,000 in the prior period, an increase of $1,775,000, or 38%.
Product Revenue: For the three months ended September 30, 2026, product revenue was $2,078,000 compared to $1,603,000 in the prior period, an increase of $475,000, or 30%. For the nine months ended September 30, 2026, product revenue was $5,246,000 compared to $3,255,000, an increase of $1,991,000, or 61%. This was driven by higher demand across nearly all of our equipment classes.
Service Revenue: For the three months ended September 30, 2026, service revenue was $415,000 compared to $409,000 in the prior period, an increase of $6,000, or 1%. For the nine months ended September 30, 2026, service revenue was $1,148,000 compared to $1,364,000 in the prior period, a decrease of $216,000, or 16%, reflecting the timing of decontamination project completions and service engagements in the period.
Domestic Revenue: For the three months ended September 30, 2026, domestic revenue was $1,921,000 compared to $1,280,000 in the prior period, an increase of $641,000, or 50%. For the nine months ended September 30, 2026, domestic revenue was $5,078,000 compared to $3,294,000 in the prior period, an increase of $1,784,000, or 54%. This was driven by new customer wins across major pharmaceutical and healthcare companies.
International Revenue: For the three months ended September 30, 2026, international revenue was $572,000 compared to $732,000 in the prior period, a decrease of $160,000, or 22%. For the nine months ended September 30, 2026, international revenue was $1,316,000 compared to $1,325,000 in the prior period, a decrease of $9,000, or 1%. International revenue reflected our global reach, with sales in Mexico, Canada, South America, the United Kingdom and Asia, among other markets.
|
| For the Three Months Ended |
|
|
| |||||||||||
Revenue by type (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
|
| % Change |
| ||||
Product |
| $ | 2,078 |
|
| $ | 1,603 |
|
| $ | 475 |
|
|
| 30 | % |
Service |
|
| 415 |
|
|
| 409 |
|
|
| 6 |
|
|
| 1 | % |
Total |
| $ | 2,493 |
|
| $ | 2,012 |
|
| $ | 481 |
|
|
| 24 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| For the Three Months Ended |
| |||||||||||||
Geographic revenue (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
|
| % Change |
| ||||
United States |
| $ | 1,921 |
|
| $ | 1,280 |
|
| $ | 641 |
|
|
| 50 | % |
International |
|
| 572 |
|
|
| 732 |
|
|
| (160 | ) |
| (22%) |
| |
Total |
| $ | 2,493 |
|
| $ | 2,012 |
|
| $ | 481 |
|
|
| 24 | % |
|
| For the Nine Months Ended |
|
|
| |||||||||||
Revenue by type (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
|
| % Change |
| ||||
Product |
| $ | 5,246 |
|
| $ | 3,255 |
|
| $ | 1,991 |
|
|
| 61 | % |
Service |
|
| 1,148 |
|
|
| 1,364 |
|
|
| (216 | ) |
| (16%) |
| |
Total |
| $ | 6,394 |
|
| $ | 4,619 |
|
| $ | 1,775 |
|
|
| 38 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| For the Nine Months Ended |
|
| ||||||||||||
Geographic revenue (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
|
| % Change |
| ||||
United States |
| $ | 5,078 |
|
| $ | 3,294 |
|
| $ | 1,784 |
|
|
| 54 | % |
International |
|
| 1,316 |
|
|
| 1,325 |
|
|
| (9 | ) |
| (1%) |
| |
Total |
| $ | 6,394 |
|
| $ | 4,619 |
|
| $ | 1,775 |
|
|
| 38 | % |
| 33 |
| Table of Contents |
Cost of Sales and Gross Profit
The following discussion presents cost of sales, gross profit and gross margin for the three and nine months ended September 30, 2026 compared to the same periods in 2025.
Gross margin decreased from 61.2% to 59.0% and from 61.9% to 57.7% for the three and nine months ended September 30, 2026, respectively, compared to the prior period. The decrease reflects strategic price discounts to drive equipment adoption. Management views these factors as temporary, as growth in recurring high-margin BIT Solution consumable sales is expected to support margin recovery in future periods.
|
| For the Three Months Ended |
|
|
| |||||||||||
Results of Operations (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
|
| % Change |
| ||||
Revenue |
| $ | 2,493 |
|
| $ | 2,012 |
|
| $ | 481 |
|
|
| 24 | % |
Cost of sales |
|
| 1,023 |
|
|
| 780 |
|
|
| 243 |
|
|
| 31 | % |
Gross profit |
| $ | 1,470 |
|
| $ | 1,232 |
|
| $ | 238 |
|
|
| 19 | % |
Gross margin |
|
| 59.0 | % |
|
| 61.2 | % |
|
| - |
|
|
|
| |
|
| For the Nine Months Ended |
|
|
| |||||||||||
Results of Operations (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
|
| % Change |
| ||||
Revenue |
| $ | 6,394 |
|
| $ | 4,619 |
|
| $ | 1,775 |
|
|
| 38 | % |
Cost of sales |
|
| 2,707 |
|
|
| 1,758 |
|
|
| 949 |
|
|
| 54 | % |
Gross profit |
| $ | 3,687 |
|
| $ | 2,861 |
|
| $ | 826 |
|
|
| 29 | % |
Gross margin |
|
| 57.7 | % |
|
| 61.9 | % |
|
| - |
|
|
|
| |
Operating Expenses
The following discusses operating expenses by category for the three and nine months ended September 30, 2026 compared to the same periods in 2025.
Total operating expenses decreased $113,000 and $542,000 for the three and nine months ended September 30, 2026 compared to the prior year period. The decrease was primarily driven by lower general and administrative expenses of $290,000 and $810,000, respectively, reflecting reduced credit loss expense, offset by an increase in professional fees due to various strategic and financing initiatives. While management continues to actively manage costs, revenue growth remains the primary driver of the Company's path to profitability.
|
| For the Three Months Ended |
|
|
| |||||||
Operating expenses (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
| |||
Professional fees |
| $ | 276 |
|
| $ | 185 |
|
| $ | 91 |
|
Depreciation and amortization |
|
| 48 |
|
|
| 68 |
|
|
| (20 | ) |
Selling expenses |
|
| 197 |
|
|
| 144 |
|
|
| 53 |
|
Research and development |
|
| 42 |
|
|
| 11 |
|
|
| 31 |
|
Consulting fees |
|
| 95 |
|
|
| 73 |
|
|
| 22 |
|
General and administrative |
|
| 782 |
|
|
| 1,072 |
|
|
| (290 | ) |
Total operating expenses |
| $ | 1,440 |
|
| $ | 1,553 |
|
| $ | (113 | ) |
|
| For the Nine Months Ended |
|
|
| |||||||
Operating expenses (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
| |||
Professional fees |
| $ | 801 |
|
| $ | 589 |
|
| $ | 212 |
|
Depreciation and amortization |
|
| 151 |
|
|
| 206 |
|
|
| (55 | ) |
Selling expenses |
|
| 617 |
|
|
| 630 |
|
|
| (13 | ) |
Research and development |
|
| 137 |
|
|
| 139 |
|
|
| (2 | ) |
Consulting fees |
|
| 341 |
|
|
| 215 |
|
|
| 126 |
|
General and administrative |
|
| 2,480 |
|
|
| 3,290 |
|
|
| (810 | ) |
Total operating expenses |
| $ | 4,527 |
|
| $ | 5,069 |
|
| $ | (542 | ) |
| 34 |
| Table of Contents |
Liquidity and Capital Resources
The following table presents key liquidity and capital measures as of September 30, 2026 compared to December 31, 2025. Working capital increased $924,000 to $1,948,000 and cash and cash equivalents increased $107,000. Total shareholders’ equity increased $3,424,000 to $4,013,000, and convertible notes decreased $2,320,000 to $592,000, primarily as a result of the conversion of $2.5 million of the 2023 Notes into common stock and proceeds from our equity line of credit. Accounts receivable increased by approximately $1.9 million, primarily reflecting increased sales activity during the third quarter of 2026.
Liquidity metrics (in thousands) |
| September 30, 2026 |
|
| December 31, 2025 |
|
| Change |
| |||
Cash and cash equivalents |
| $ | 195 |
|
| $ | 88 |
|
| $ | 107 |
|
Accounts receivable, net |
| $ | 2,593 |
|
| $ | 689 |
|
| $ | 1,904 |
|
Inventories, net (Note 3) |
| $ | 2,381 |
|
| $ | 2,926 |
|
| $ | (545 | ) |
Working capital |
| $ | 1,948 |
|
| $ | 1,024 |
|
| $ | 924 |
|
Total shareholders’ equity |
| $ | 4,013 |
|
| $ | 589 |
|
| $ | 3,424 |
|
Total debt - convertible notes |
| $ | 592 |
|
| $ | 2,912 |
|
| $ | (2,320 | ) |
Accumulated deficit |
| $ | (59,434 | ) |
| $ | (58,052 | ) |
| $ | (1,382 | ) |
For the nine months ended September 30, 2026, we incurred a net loss of approximately $1.38 million, including an approximately $149,000 non-cash loss on extinguishment of convertible debt, and used cash in operations of approximately $1.56 million. Our accumulated deficit as of September 30, 2026 was approximately $59.4 million. The non-cash loss on extinguishment did not directly affect the Company's cash or working capital during the period.
These conditions raise substantial doubt about our ability to continue as a going concern within the next twelve months after the date these financial statements are issued. The condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from the outcome of this uncertainty. See Note 2 to our condensed consolidated financial statements for further discussion of the going concern assessment.
The approximately $0.9 million increase in working capital during the nine months ended September 30, 2026 was primarily attributable to net proceeds of approximately $2.1 million received under the Company's Equity Line of Credit, partially offset by cash used in operating activities. The approximately $149,000 non-cash loss on extinguishment of convertible debt did not affect working capital during the period.
Equity Purchase Agreement — Hudson Global Ventures, LLC
On November 5, 2025, the Company entered into a Purchase Agreement with Hudson Global, pursuant to which the Company has the right, but not the obligation, to sell to Hudson Global up to $20,000,000 of shares of Common Stock over a 24-month Commitment Period. See Note 9 for additional information on the Purchase Agreement.
During the nine months ended September 30, 2026, pursuant to the ELOC, we issued 1,558,642 shares of Common Stock and received aggregate net proceeds of $2,063,421. The shares were issued pursuant to the Form S-3 registration statement (File No. 333-291563) and the prospectus supplement dated December 11, 2025. The Company intends to use the proceeds for working capital and general corporate purposes.
Management’s Plan to Address Going Concern
For a full discussion of management's plan to address the going concern conditions, including the ELOC, shelf registration, stock split, convertible note management, pipeline conversion and cost management initiatives, refer to Note 2 to our condensed consolidated financial statements.
Debt and Contractual Obligations
Our outstanding debt consists of $635,000 in convertible notes at 12% per annum, maturing 2028–2030. Full terms are disclosed in Note 8 to our condensed consolidated financial statements.
A breakdown of our statement of cash flows for the nine months ended September 30, 2026 and 2025 is provided below:
Cash flows for the period (in thousands) |
| September 30, 2026 |
|
| September 30, 2025 |
|
| Change |
| |||
Net cash (used) in operating activities |
| $ | (1,559 | ) |
| $ | (577 | ) |
| $ | (982 | ) |
Net cash (used) in investing activities |
|
| (29 | ) |
|
| (133 | ) |
|
| 104 |
|
Cash provided by financing activities |
|
| 1,696 |
|
|
| 535 |
|
|
| 1,161 |
|
Net increase (decrease) in cash |
| $ | 107 |
|
| $ | (175 | ) |
| $ | 282 |
|
| 35 |
| Table of Contents |
Operating Activities
Net cash used in operating activities was approximately $1.56 million for the nine months ended September 30, 2026, compared with approximately $577,000 in the prior-year period. The change was primarily driven by a $1.89 million increase in accounts receivable, reflecting growth in sales during the period. Net loss for the period included an approximately $149,000 non-cash loss on extinguishment of convertible debt, which did not affect cash used in operating activities. These uses of cash were partially offset by an approximately $1.31 million increase in accounts payable and accrued expenses and an approximately $642,000 reduction in inventories.
Investing Activities
Net cash (used in) investing activities was ($29,000) for the nine months ended September 30, 2026, consisting of equipment purchases and a new patent granted in Japan. Net cash (used in) investing activities was ($133,000) for the nine months ended September 30, 2025, consisting of equipment purchases, patents and trademarks.
Financing Activities
Net cash provided by financing activities was $1,696,000 for the nine months ended September 30, 2026, compared to $535,000 in the prior year period which was raised through convertible note issuances. For the nine months ended September 30, 2026, net financing activities reflected ELOC proceeds of $2,063,000 net of issuance costs offset by repayments of $367,000 on the sale of future receipts agreement with Agile Capital.
Critical Accounting Estimates
Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The estimation process requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. Actual results could differ materially from our estimates.
The SEC defines critical accounting estimates as those that are, in management's view, most important to the portrayal of our financial condition and results of operations and the most demanding of our judgment. We consider the following estimates to be critical to an understanding of our consolidated financial statements and the uncertainties associated with the complex judgments made by us that could impact on our results of operations, financial position and cash flows.
Going Concern Assessment
The assessment of our ability to continue as a going concern is the most significant judgment reflected in our financial statements for the nine months ended September 30, 2026. Under ASC 205-40, management is required to evaluate whether there is substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued. This evaluation requires management to consider all available information about the future, including the Company's projected cash flows, planned capital raising activities, anticipated operating improvements, and the probability and timing of successfully executing those plans.
For the nine months ended September 30, 2026, we recorded a net loss of approximately $1,382,000, which included an approximately $149,000 non-cash loss on extinguishment of convertible debt recognized during the third quarter. As of September 30, 2026, we had approximately $195,000 of cash and cash equivalents and an accumulated deficit of approximately $59.4 million. Based on these conditions, management concluded that substantial doubt exists about our ability to continue as a going concern within one year after the issuance of these financial statements. Management's conclusion is based on projected cash flows that consider the potential utilization of the $20 million ELOC with Hudson Global Ventures, LLC entered into in November 2025, other potential financing opportunities, and anticipated revenue growth from our active commercial pipeline.
If our assumptions regarding capital availability, revenue timing or operating costs prove incorrect, the Company's liquidity position could deteriorate more rapidly than projected, and there can be no assurance that the going concern doubt will be resolved within the anticipated timeframe. See Note 2 to the consolidated financial statements for further discussion.
| 36 |
| Table of Contents |
Revenue Recognition
We recognize revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy the performance obligations.
We must use judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; (b) the transaction price under step (iii) above; and (c) the stand-alone selling price for each performance obligation for the allocation of transaction price under step (iv) above.
Title and risk of loss generally pass to our customers upon shipment. Shipping and handling costs charged to customers are included in product revenues, and the associated expenses are treated as fulfillment costs included in cost of revenues. Revenues are reported net of sales taxes collected from customers.
Product revenue includes sales from our standard and customized equipment, BIT Solution and accessories. Revenue is recognized upon transfer of control of promised products to customers in an amount that reflects the consideration we expect to receive. Service and training revenue includes sales from our high-level decontamination and service engagements, equipment validation and customer training, and is recognized as the agreed-upon services are rendered.
A growing portion of our revenue is derived from our SIS and CES, which may involve multiple performance obligations including equipment supply, installation, validation and ongoing service. For these arrangements, management exercises significant judgment in identifying and allocating the transaction price among the distinct performance obligations and in determining the point at which control transfers to the customer. Delays in project completion or customer acceptance for these arrangements can affect the timing of revenue recognition and contribute to variability in our quarterly results.
We also record estimated allowances for sales returns, based on historical averages of return activity applied to our quarterly moving sales. As of September 30, 2026 and December 31, 2025, we recorded allowances of $117,137 and $47,844, respectively. The increase in the allowance was due to higher equipment sales during the current year period and the inclusion of repossessed equipment in our return history.
As of September 30, 2026 and December 31, 2025, deferred revenue totaled approximately $171,000 and $424,000, respectively, representing contracted amounts for which performance obligations had not yet been satisfied. The decrease in deferred revenue reflects the progress within our SIS and CES project pipeline and the timing of project milestones. Changes in assumptions regarding the timing of project completion or customer acceptance could affect the amount and timing of revenue recognized in future periods.
Arrangements with Multiple Performance Obligations
Our contracts with customers may include multiple performance obligations. We enter into contracts that can include various combinations of products and services, which are primarily distinct and accounted for as separate performance obligations. This is particularly the case for our SIS and CES, which may involve equipment supply, installation, validation services and ongoing maintenance components. Where a contract contains multiple performance obligations, we allocate the total transaction price to each distinct performance obligation based on its relative stand-alone selling price, estimated using observable market prices where available or using a cost-plus-margin approach where direct market evidence is not available.
Significant Judgments
Our contracts with customers for products and services often dictate the terms and conditions of when control of the promised products or services is transferred to the customer and the amount of consideration to be received in exchange for those products and services. For standard equipment and BIT Solution sales, control transfers and revenue is recognized at the point of shipment, which is when title and risk of loss pass to the customer. For service and training arrangements, revenue is recognized as services are rendered. For SIS and CES arrangements involving installation and validation milestones, management exercises judgment in determining the point at which control transfers, which may be upon completion of installation, customer acceptance, or satisfaction of specific contractual milestones. The timing of these measures can affect the period in which revenue is recognized and contribute to variability in our quarterly results. We also record an estimated allowance for anticipated product returns, determined using a specific identification method based on subsequent return activity and historical average calculations.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the accompanying consolidated financial statements and notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate our estimates, including those related to the allowance for credit losses, inventory obsolescence reserves, allowances for sales returns, the fair value of stock-based awards, the realizability of deferred tax assets, the useful lives of intangible assets and property and equipment, and contingent liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
| 37 |
| Table of Contents |
Accounts Receivable
Accounts receivable are stated at the amount management expects to collect from outstanding balances. We do not generally require collateral to support customer receivables. In accordance with ASC 326, Current Expected Credit Losses, we estimate and record expected credit losses over the entire life of our accounts receivable, considering historical collection experience, customer creditworthiness, specific customer risk, current economic conditions and reasonable and supportable forecasts of future conditions. We make a risk-based evaluation of collectability at the point of sale, which is further reviewed on both an individual and collective basis during each reporting period.
As of September 30, 2026, net accounts receivable totaled $2,592,871 compared to $689,153 as of December 31, 2025. The increase reflects higher revenue levels in the current period. Management exercises judgment in determining the appropriate allowance for credit losses, and changes in the creditworthiness of our customers, deterioration in economic conditions, or the loss of a significant customer relationship could result in allowance adjustments that materially affect our results of operations in a given period.
Inventories
Inventories are valued at the lower of cost or net realizable value using the first-in, first-out method. Inventories consist primarily of finished goods. We review inventory on an ongoing basis, considering factors such as deterioration, obsolescence, and anticipated future customer demand, and we record an allowance for estimated losses when facts and circumstances indicate that particular inventory items may not be usable or saleable. The determination of the appropriate reserve requires management to exercise judgment regarding expected future demand, the useful life of specific inventory items, and the potential for product design changes or regulatory developments that could render existing inventory obsolete.
As of September 30, 2026 and December 31, 2025, our recorded reserve for obsolete inventory was $500,000 and $500,000, respectively. The carrying reserve of $500,000 as of September 30, 2026 reflects historical accounting treatment and estimation methodologies established in prior fiscal periods under ASC 330 and SEC Staff Accounting Bulletin (SAB) Topic 5.BB. Under SAB Topic 5.BB, an inventory write-down establishes a new cost basis that cannot subsequently be written back up, regardless of subsequent operational improvements or changes in forward demand expectations.
While the recorded allowance of $500,000 is maintained on the Condensed Consolidated Balance Sheet to satisfy GAAP accounting requirements regarding prior cost-basis adjustments, management continuously evaluates the underlying economic exposure of its inventory population. Based on recent operational developments—including year-to-date unit depletion, internal conversion of equipment to active customer configurations, and expanding commercial pipeline conversion—The Company will derecognize the associated carrying reserves as underlying inventory units are sold, consumed, or otherwise disposed of in the ordinary course of business. If actual demand for our products differs materially from our forecasts, or if future changes in our product offerings render existing inventory obsolete, additional write-downs may be required.
Long-Lived Assets Including Acquired Intangible Assets
We assess long-lived assets, including property and equipment and acquired intangible assets, for potential impairment at the end of each fiscal year or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount of the asset to the estimated future undiscounted cash flows expected to be generated by the asset. If an asset is considered impaired, the impairment charge recognized equals the amount by which the carrying value exceeds the asset's estimated fair value, which we determine using an income approach based on an internally developed discounted cash flow model. Key assumptions in this model include projected revenues and operating expenses, long-term growth rates, and estimated discount rates. These assumptions are based on our historical experience, industry data, and management's expectations about future business conditions.
We noted no long-lived asset impairment charges for the three and nine months ended September 30, 2026 and 2025. Management's impairment analysis considered the going concern conditions described above and concluded that projected undiscounted cash flows, based on our current operating plan and capital raising assumptions, continue to support the carrying values of our long-lived assets. Changes in our revenue outlook, discount rates or other key assumptions could result in impairment charges in future periods.
Convertible Notes and Debt Discount
As of September 30, 2026, the Company had outstanding convertible notes with an aggregate principal balance of approximately $635,000, consisting of $100,000 of the 2023 Notes and $535,000 of the 2025 Notes, before unamortized debt discounts. The convertible notes bear interest at 12% per annum and mature on the fifth anniversary of their respective issuance dates.
On August 12, 2026, the Company entered into an Omnibus Amendment with certain holders of the 2023 Notes, which amended the conversion price of the 2023 Notes from $3.75 per share to $1.50 per share, as adjusted for the Company’s Reverse Stock Split. Except as expressly amended, all other terms and provisions of the 2023 Notes remain in full force and effect.
The Company determined that the August 12, 2026 Amendment constituted an extinguishment of the existing debt under ASC 470-50. Accordingly, the amended notes were measured at fair value as of the amendment date. The fair value measurement required significant judgment and incorporated assumptions regarding the Company’s credit risk, expected term, stock price volatility, mandatory conversion provisions and other contractual features of the notes. Changes in these assumptions could have resulted in a materially different fair value and corresponding loss on extinguishment.
The fair value of the amended notes was estimated at approximately $2.52 million as of August 12, 2026, compared with a net carrying amount of approximately $2.37 million immediately prior to the Amendment. As a result, the Company recognized an approximately $149,000 non-cash loss on extinguishment of convertible debt during the three months ended September 30, 2026. Subsequent to the Amendment, holders of $2.5 million aggregate principal amount of the amended 2023 Notes elected to convert their notes into approximately 1.67 million shares of the Company’s common stock. See Note 8, Convertible Debt, for additional information.
| 38 |
| Table of Contents |
Stock-Based Compensation
We account for stock-based compensation in accordance with ASC 718, Compensation — Stock Compensation. Stock-based awards, including stock options, restricted stock units and shares issued for services, are measured at their estimated fair value on the grant date and recognized as expense over the requisite service period. For stock options and warrant awards, fair value is determined using the Black-Scholes option pricing model, which requires management to make assumptions regarding the expected volatility of our common stock, the expected term of the award, the risk-free interest rate and expected dividend yield. We assume a dividend yield of zero, as we have not paid and do not intend to pay cash dividends on our common stock. Expected volatility is based on the historical volatility of our common stock over a period commensurate with the expected term of the award. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the grant date for the applicable expected term.
During the nine months ended September 30, 2026, we recognized approximately $90,000 of stock-based compensation expense, including shares issued to directors and equity compensation expense. Changes in the assumptions used in the Black-Scholes model, or modifications to existing awards, could result in materially different fair value estimates and compensation expense amounts.
Income Taxes and Valuation Allowance
We account for income taxes in accordance with ASC 740, Income Taxes, using the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and tax bases of assets and liabilities, as well as for net operating loss and tax credit carryforwards. Deferred tax assets are reduced by a valuation allowance to the extent that management concludes it is more likely than not that some or all of the deferred tax assets will not be realized.
We recorded no income tax expense or benefit for the three and nine months ended September 30, 2026 and 2025 due to our net operating losses and the maintenance of a full valuation allowance against our net deferred tax assets. As of September 30, 2026, our total valuation allowance was approximately $10,065,000, an increase of approximately $346,000 from $9,719,000 as of December 31, 2025, primarily reflecting additional deferred tax assets arising from current-period losses. As of December 31, 2025, we had available federal net operating loss carryforwards of approximately $27,911,000 and state net operating loss carryforwards of approximately $26,405,000. Net operating losses generated after December 31, 2017 carry forward indefinitely; those generated prior to 2018 expire at various dates through 2037. NOLs generated after 2017 carry forward indefinitely but are limited to offset 80% of taxable income in any given year.
The judgment to maintain a full valuation allowance is the most significant estimate within our income tax accounting. This judgment is based on our cumulative history of operating losses, our going concern conditions, and the uncertainty surrounding the timing and amount of future taxable income sufficient to realize these assets. We reassess this conclusion at each reporting date. If our operating results improve materially and we conclude it is more likely than not that a portion of our deferred tax assets will be realized, we would reduce the valuation allowance accordingly, which could result in a material income tax benefit in the period of that determination. We adopted ASU 2023-09, Improvements to Income Tax Disclosures, on a prospective basis as of January 1, 2025. The required disaggregated rate reconciliation and taxes paid disclosures were included in our 2025 Form 10-K as filed on March 31, 2026.
Recently adopted accounting standards
In July 2025, the FASB issued Accounting Standards Update (“ASU”) No. 2025-05, Financial Instruments Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This ASU provides a practical expedient permitting an entity to assume that conditions at the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current-classified accounts receivable and contract assets. The ASU is effective for annual periods beginning after December 15, 2025, including interim periods within those fiscal years, with early adoption permitted. We adopted ASU 2025-05 in the first quarter of 2026 on a prospective basis and did not elect the practical expedient. The adoption of this ASU did not have a material impact on the Company's consolidated financial statements or on the allowance for credit losses as of September 30, 2026.
Recently issued accounting standards not yet adopted
In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40), subsequently clarified by ASU No. 2025-01 issued in January 2025. This ASU requires disaggregated disclosure of specific expense categories, including purchases of inventory, employee compensation, depreciation and amortization, within relevant income statement captions, and also requires disclosure of total selling expenses and their definition. The ASU is effective for annual periods beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating the provisions of this ASU, which will likely result in additional required disclosures once adopted.
In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The ASU clarifies interim disclosure requirements and the applicability of Topic 270. The objective of the amendments is to provide further clarity about the current interim disclosure requirements. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Adoption of this ASU can be applied either a prospective or a retrospective approach. Early adoption is permitted. We are currently evaluating the provisions of this ASU and do not expect this ASU to have a material impact on our consolidated financial statements.
In December 2025, the FASB issued ASU No. 2025-12, Codification Improvements. The ASU addresses thirty-three items, representing the changes to the Codification that (1) clarify, (2) correct errors, or (3) make minor improvements. Generally, the amendments in this Update are not intended to result in significant changes for most entities. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2026. The adoption method of this ASU may vary, on an issue-by-issue basis. Early adoption is permitted. We are currently evaluating the provisions of this ASU and do not expect this ASU to have a material impact on our consolidated financial statements.
| 39 |
| Table of Contents |
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not Applicable.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management conducted an evaluation of the effectiveness of our disclosure controls and procedures (as is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Our disclosure controls and procedures are intended to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Principal Executive Officer and Principal Financial Officer, to allow timely decisions regarding required disclosures.
Based on that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective at the reasonable assurance level because we have identified a material weakness in our internal control over financial reporting as discussed below, and such material weakness has not been remediated as of September 30, 2026. Our management has concluded that the financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.
Our disclosure controls and procedures are designed to provide reasonable assurance of achieving the desired control objectives. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.
Material Weakness in Internal Control Over Financial Reporting
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has concluded that, as of September 30, 2026, we did not maintain effective controls over the preparation, review, presentation and disclosure of our financial statements. Specifically, we noted the following:
| · | There are limited resources within the finance and accounting departments with sufficient knowledge and experience in applying U.S. GAAP, including but not limited to developing appropriate accounting estimates, reserves, and allowances in a timely manner and to maintain proper segregation of duties; and, |
|
|
|
| · | Policies and procedures with respect to the review, supervision and monitoring of our accounting and SEC reporting functions were either not designed and in place or not operating effectively. |
These control deficiencies, if not remediated, could result in a misstatement to the annual or interim consolidated financial statements which would result in a material misstatement of the annual or interim consolidated financial statements that would not be prevented or detected. Accordingly, our management has determined that these control deficiencies constitute material weaknesses.
| 40 |
| Table of Contents |
Remediation - Progress and Actions Taken
Management, with oversight from our Audit Committee, implemented specific remediation actions during fiscal year 2025 and 2026 which are fully disclosed in our previously filed Form 10-K. We continue to monitor and track progress on a quarterly basis in the following areas:
| · | Finance Leadership Transition: Continue to strengthen our finance and accounting function, including enhanced financial reporting, internal controls, budgeting and forecasting, and oversight of the quarterly close and SEC reporting processes. Subsequent to quarter-end, Niroshan Srirathan was appointed Chief Financial Officer in October 2026. Management believes the Company's current finance leadership structure and resources are appropriate for its present operations and reporting requirements. The Company will continue to evaluate the finance function as its operations and reporting requirements evolve. |
|
|
|
| · | Sales Returns Reserve Controls: Enforce controls over our return policy, including written return authorization, a 20-day return window and restocking charges, and formalized quarterly review of the returns reserve and credit memos. |
|
|
|
| · | Written Accounting Policies & Close Procedures: Update written accounting policies and procedures, including comprehensive controls documentation each period and improved processes for quarter-end close and revenue recognition (ASC 606). |
|
|
|
| · | Enhanced Technical Research Capabilities: Integrate AI-assisted technical research tools to support complex U.S. GAAP research and financial statement disclosures. |
|
|
|
| · | Inventory Control & Physical Counts: Establish and enforce monthly physical inventory counts and formalize quarterly reserve review procedures for slow-moving and excess inventory under ASC 330. |
|
|
|
| · | Cash Management & Monitoring: Maintain a 13-week rolling cash flow forecast and daily bank reconciliations to strengthen treasury monitoring and liquidity tracking. |
|
|
|
| · | Organizational Restructure & Staff Alignment: Conduct a thorough staff review and organizational restructure, establishing an additional layer of management oversight to enhance supervision, realign roles, and enforce proper segregation of duties within the accounting and finance function. |
|
|
|
| · | Continued Training & Third-Party Technical Support: Expand technical accounting training and retain third-party advisory support for complex reporting topics |
|
|
|
| · | Executive Oversight & Reserve Monitoring: Institute weekly executive finance meetings to actively track cash management, evaluate liquidity, and perform ongoing reviews of key management estimates, including inventory and CECL reserves (with ongoing Q4 initiatives focused on updating ERP user access controls). |
While the material weaknesses had not been fully remediated as of September 30, 2026, management believes the actions taken to date represent meaningful progress in addressing the identified control deficiencies. Full remediation will require operating these enhanced controls for a sufficient period of time and testing their operational effectiveness. Management and the Audit Committee will continue to evaluate and test our internal financial reporting controls throughout fiscal year 2026.
Changes in Internal Control Over Financial Reporting
During the three months ended September 30, 2026 and except as disclosed above regarding the material weaknesses and related remediation plans, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
| 41 |
| Table of Contents |
PART II: OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on the results of our operations, financial position or cash flows. Regardless of the outcome, any litigation could have an adverse impact on us due to defense and settlement costs, diversion of management resources and other factors.
Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed under Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 14, 2026, and Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026.
| 42 |
| Table of Contents |
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.
During the three months ended September 30, 2026, following the Omnibus Amendment described in Item 5 below, holders of $2,500,000 aggregate principal amount of the 2023 Notes elected to convert their notes at the amended conversion price of $1.50 per share into an aggregate of 1,666,655 shares of Common Stock, of which 1,000,000 shares were issued without registration under the Securities Act of 1933, as amended (the “Securities Act”). The unregistered shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) and/or Regulation D of the Securities Act, as the shares were issued to existing holders of the Company’s securities in exchange for outstanding securities, no commission or other remuneration was paid or given directly or indirectly for soliciting the conversions. The Company received no cash proceeds from the conversions.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
10b5-1 Arrangements
To the best of the Company’s knowledge during the fiscal quarter ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Amendment to Convertible Promissory Notes
On August 12, 2026, the Company entered into an Omnibus Amendment (the “Omnibus Amendment”) with the holders of the 2023 Notes, which amended the conversion price of the 2023 Notes from $3.75 to $1.50 per share, subject to adjustment in accordance with the terms of the 2023 Notes. Except as expressly amended, all other terms and provisions of the 2023 Notes remain in full force and effect.
Item 6. Exhibits.
The documents listed in the Exhibit Index of this Form 10-Q are incorporated herein by reference.
| 43 |
| Table of Contents |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| TOMI ENVIRONMENTAL SOLUTIONS, INC. | |||
| Date: November 17, 2026 | By: | /s/ HALDEN S. SHANE | |
|
| Halden S. Shane | |
| Chief Executive Officer (Principal Executive Officer) | |||
| Date: November 17, 2026 | By: | /s/ NIROSHAN Srirathan | |
|
| Niroshan Srirathan | |
| Chief Financial Officer | |||
| (Principal Financial Officer and Principal Accounting Officer) |
| 44 |
| Table of Contents |
EXHIBIT INDEX
Exhibit Number |
| Description of Exhibit |
| Form |
| File No. |
| Date |
| Exhibit |
| Filed Herewith |
3.1 |
| Articles of Restatement of the Registrant, effective October 6, 2009 |
| S-1 |
| 333-162356 |
| 10/6/2009 |
| 3.1 |
|
|
3.2 |
| Articles of Amendment of Articles of Incorporation of the Registrant, effective October 24, 2011 |
| 8-K |
| 000-09908 |
| 11/07/2011 |
| 3 |
|
|
3.3 |
| Articles of Amendment of Articles of Incorporation of the Registrant, effective September 10, 2020 |
| 8-K |
| 000-09908 |
| 9/14/2020 |
|
|
|
|
3.4 |
| Articles of Amendment to Articles of Incorporation of the Registrant, effective July 20, 2026 |
| 8-K |
| 000-09908 |
| 7/20/2026 |
| 3.1 |
|
|
3.5 |
| Amended Bylaws of the Registrant, adopted effective November 2, 2007 |
| 10-Q |
| 000-09908 |
| 5/16/2016 |
| 3.2 |
|
|
3.6 |
| Amendment to Amended Bylaws of the Registrant, adopted effective January 29, 2016 |
| 8-K |
| 000-09908 |
| 2/1/2016 |
| 3.2 |
|
|
10.1+ |
| Offer Letter, dated October 11, 2026, by and between the Registrant and Niroshan Srirathan |
|
|
|
|
|
|
|
|
| X |
31.1 |
| Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
|
|
|
|
|
|
|
| X |
31.2 |
| Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
|
|
|
|
|
|
|
| X |
32.1# |
| Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|
|
|
|
|
|
|
|
| X |
32.2# | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||||||||
101.INS |
| XBRL Instance Document |
|
|
|
|
|
|
|
|
| X |
101.SCH |
| XBRL Taxonomy Extension Schema |
|
|
|
|
|
|
|
|
| X |
101.CAL |
| XBRL Taxonomy Extension Calculation Linkbase |
|
|
|
|
|
|
|
|
| X |
101.DEF |
| XBRL Taxonomy Extension Definition Linkbase |
|
|
|
|
|
|
|
|
| X |
101.LAB |
| XBRL Taxonomy Extension Label Linkbase |
|
|
|
|
|
|
|
|
| X |
+ Indicates a management contract or compensatory plan.
# This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, or the Exchange Act.
| 45 |